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Lung cancer is the leading cause of tumor related death worldwide. Lung AdenoCarcinoma 
(AC) histotype is the most diffused, corresponding to 60% of Non-Small-Cell Lung Cancers 
(NSCLCs), and its treatment is, generally, based on resection combined with platinum-
doublet based chemotherapy. However chemotherapeutic treatment harbours some limitations 
such as the lack of specificity for tumor cells and the frequent and severe dose-limiting 
toxicities. In order to solve these limitations, last years have seen the development of targeted 
therapies, treatments capable to specifically target the main molecular alterations driving 
tumorigenesis. The most diffused targeted therapies in lung ACs are small-molecule tyrosine 
kinase inhibitors (TKIs) acting against Epidermal Growth Factor Receptor (EGFR) and 
Anaplastic Lymphoma receptor tyrosine Kinase (ALK) alterations. More recently, targeted 
drugs against ROS1, Human Epidermal growth factor Receptor 2 gene (HER2), and BRAF 
have been introduced in the clinical setting, whereas the therapies against Kirsten Rat sarcoma 
viral oncogene homolog (KRAS) mutations, the most frequent in lung AC, are still under 
development. These data highlight that the molecular characterization of histological or 
cytological samples is strictly necessary to define a possible response to targeted drugs. In last 
two years a new important advancement was accepted by FDA: the characterization of 
molecular markers, especially EGFR, in liquid biopsies. These analyses have many 
advantages compared to tissue biopsies testing: they are less invasive, they better reflect 
tumor heterogeneity and they can be repeated serially overtime. Liquid biopsies are 
fundamental for patients experiencing secondary resistance to EGFR inhibitors but can be 
used in upfront patients as well, especially in the cases without tissue material available. 
The aim of my project was to improve the clinical care of patients affected by lung AC, by 
enhancing the characterization of EGFR mutations in one side and by characterizing the 
expression of a new, putative marker, the tyrosine kinase-like orphan receptor-1 (ROR1) in 
the other side. In order to improve the determination of EGFR in lung AC specimens, we 
decided to test and validate a new methodology characterized by high sensitivity, simplicity 
of execution and uniformity in the interpretation of results. The need of a more sensitive kit is 
due to the fact that lung AC samples are generally represented by small biopsies characterized 
by poor quantity and quality of cell tumor content. In addition, cancer cells are very often 
dispersed in a high quantity of normal cells, leading the biopsy difficult to be considered 
representative of the whole tumor. In particular, in collaboration with a Danish company 
(PentaBase ApS), I developed new real-time based assays (SensiScreen
®
) containing reagents 
capable to increase specificity and sensitivity of EGFR mutation detection. Simplex assays 
(for G719A, G719C, G719S, S768I, T790M, L858R, L861Q mutations) and multiplex assays 
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(for G719 mutations, exon 19 deletions or exon 20 insertions), specific for tissue and liquid 
biopsies, were validated on plasmids and on different dilution points of DNA extracted from 
mutated cell lines. The validation revealed a limit of detection (LOD) that is between 0.1% 
and 1%, corresponding to the detection of until 1 copy of mutant DNA in a wild-type (wt) 
background. Afterwards, the new methodology was tested on two retrospective lung AC 
patient cohorts: the first one characterized by 471 tissue samples and the second one by 61 
plasma, 5 serum and 39 paired tissue specimens. Before SensiScreen
®
 application the first 
cohort was characterized for EGFR, KRAS, BRAF, HER2 mutations by Direct Sequencing 
(DS), for ALK and ROS1 gene rearrangements by Fluorescent In Situ Hibridization (FISH) 
and for thyroid transcriptional factor-1 (TTF-1) expression by immunohistochemistry (IHC); 
whereas the second cohort was evaluated for EGFR by different methodologies (DS; cobas
®
, 
Roche; Ion Torrent
®
, Thermo Fisher Scientific; TheraScreen
®
, QIAGEN). In the first and 
second cohort the percentage of alterations of the various markers are in line with the data 
reported in the literature for Caucasian patients. In cohort one, by applying the two-tailed 
Fisher’s exact test for the comparison among the molecular alterations, we found a nearly 
mutual exclusivity between EGFR and KRAS mutations and a tendency of BRAF or KRAS wt 
sequences in TTF-1 positive cases. Using the new developed assays, we confirmed the EGFR 
mutations found by DS and by the other aforementioned methodologies. Most importantly, in 
the first cohort, we identified 14 additional mutations compared to DS and in the second 
cohort two new mutated cases compared to TheraScreen
®
 (QIAGEN) and cobas
® 
(Roche). 
These two patients, classified as L858R negative by TheraScreen
®
 (QIAGEN) and cobas
® 
(Roche) techniques on DNA from plasma, were subjected to a subsequent tissue biopsy for 
the molecular characterization. In tissue cobas
®
 (Roche), TheraScreen
®
 (QIAGEN) and 
SensiScreen
®
 assays demonstrated the presence of the L858R change. So we can conclude 
that the application of these highly sensitive assays may lead to address a higher number of 
patients to EGFR-inhibitors (that are more efficient in EGFR-mutant cases with respect to 
standard chemotherapies) and may also prevent the use of tissue biopsies, that can be the 
source of side effects for the patients. These conclusions suggest the adoption of the new 
methodology in the laboratories of molecular pathology because SensiScreen
®
 is a faster, 
easy-to-use and highly sensitive method for EGFR characterization in tissue and plasma 
samples.  
 
The new assay enlarges the number of lung AC patients characterized by EGFR alterations, 
however nearly 70% of patients do not harbour mutations in EGFR or in the other molecular 
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markers for which a targeted therapy has been already developed. As a consequence, as 
second aim of my PhD, we evaluated a promising marker for lung AC, ROR1. This protein 
may represent a good candidate for new drugs, currently studied in tumour cell lines, because 
it is not expressed in adult normal tissues but only in cancer and because a study in literature 
reports its association with TTF-1, the typical AC marker. We investigated ROR1 and miR-
382 (a microRNA, miRNA, involved in ROR1 inhibition) by TaqMan real-time PCR assays 
in a third retrospective cohort of 102 lung AC patients, for which we have got pathological 
and clinical data. In this cohort, we characterized EGFR, KRAS, BRAF, HER2 by DS, ALK, 
ROS1 by FISH, TTF-1 by IHC and we found alterations in percentages similar to those 
reported in the literature. Our analyses revealed ROR1 overexpression in 28.6% and miR-382 
expression in 48.1% out of the evaluable cases. In addition, by applying the two-tailed 
Fisher’s exact test, we found no correlations between ROR1 or miR-382 and the molecular-
clinical-pathological data or with the overall survival and the progression free survival, 
calculated on the basis of the chemotherapeutic treatments. Moreover, we found no significant 
statistical correlation between miR-382 and ROR1. 
 
To conclude, in our project we tried to improve the care of patients affected by lung cancer, 
firstly by the validation of a new more sensitive real-time kit for plasma and tissue, able to 
enlarge the number of EGFR mutant patients, and secondly by the evaluation of ROR1 
expression, a new marker for targeted therapies.  
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1.1) Lung cancer: epidemiology and etiology  
 
Despite the improvements in therapies and in clinical analyses seen in the last decades, lung 
cancer remains the leading cause of tumor related death worldwide. Indeed it is the neoplastic 
disease with the highest mortality. Death rates are nearly the same in males and females, 
accounting respectively for 27% and 26% out of all deceases associated to cancer 
(Cancer.org. Cancer facts and figures 2016. American Cancer Society; 2016). The mortality 
from this neoplastic disease exceeds that of breast, prostate and colorectal cancers combined 
(Miller KD et al, 2016). This is mainly due to the relevant metastatic potential that makes 
lung cancer difficult to be diagnosed before the advanced stage. 
In addition to the high mortality, it is characterized by an incidence that, in both men and 
women, is the second one after sex related tumors (i.e. prostate and breast cancers) (Travis 
WD et al, 2004; Siegel R et al, 2015; Travis WD et al, 2016). Lung cancer incidence is higher 
in men than in women but in the last years male incidence has decreased, mainly thanks to the 
diffusion of anti-smoking campaigns. Indeed both smoking prevention and smoking cessation 
can lead to a significant reduction in lung cancer development (as well as in the one of other 
cancers). In countries characterized by anti-smoking campaigns, lung cancers incidence is 
declining in men and is reaching a plateau in women (IARC website: https://www.iarc.fr/). In 
2013, men highest incidence rates were observed in North America, East Asia, Central-
Eastern and Southern Europe (ranging from 48.5 to 56.5 new cases per 100,000 inhabitants). 
While in less developed countries, the highest rates were seen in West Asia, South Africa and 
the Caribbean (ranging from 25.7 to 32.2 new cases per 100,000 inhabitants). In women the 
worldwide incidence rates of lung cancer are lower than those for men and in 2013 the highest 
rates were seen in North America and in Northern Europe (ranging from 35.8 to 37 new cases 
per 100,000 inhabitants) (Ridge CA et al, 2013). 
The overall survival (OS) for lung cancer is poor: the EUROCARE 5 study reports that, in 
European countries, lung cancer survival is low with a relative survival (RS) of 39% and 13% 
at 1 and 5 years after diagnosis, respectively (Francisci S et al, 2015). Recent data from 1999 
to 2006 show that women have better survival compared with men across all ages, 
irrespective of the histologic subtype. Indeed, in 2006, the 5-year survival rate for women 
with lung cancer was 19% compared to 14% for men (Ridge CA et al, 2013). Moreover, OS is 
higher for squamous cell carcinoma and adenocarcinomas than for small and large cell 
carcinoma (Francisci S et al, 2015). Lung cancer carcinogenesis is related to interactions of 
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both genetic and epigenetic factors leading to an uncontrolled growth of abnormal cells in 
lung tissue.  
In most of the patients the main driver is tobacco smoking, indeed the geographic and 
temporal patterns reflect tobacco consumption during last decades. In addition to tobacco 
smoking, there are also other factors (e.g. hormonal imbalance; viruses; genetic factors; 
genetic individual susceptibility; exposure to asbestos, arsenic, radon, non-tobacco-related 
polycyclic aromatic hydrocarbons and other environmental aspects) which have been 
proposed to predispose to lung cancer development. All these factors can cause genetic and 
global transcriptome changes resulting in cells characterized by aberrant pathways activation 
that can persist long term leading to dysplasia and clonal patches. Afterward, other additional 
changes bring to early stage cancer, angiogenesis, metastasis and, at the end, the increasing 
invasion brings to advanced lung cancer (Herbst RS et al, 2008). 
 
 
1.2) Lung cancer: classification 
 
Lung cancers classification should be made following 2015 World Health Organization 
(WHO) guidelines and International Association for the Study of Lung Cancer/American 
Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) recommendations.  
Lung cancers, on the basis of morphology, can be subdivided into Non-Small-Cell Lung 
Cancers (NSCLCs) and Small-Cell Lung Cancers (SCLCs). The percentage of lung cancers 
classified as NSCLCs is equal to 80-85% (Miller KD et al, 2016). Tissue morphology, 
analyzed by a pathologist, and immunohistochemistry (IHC) staining allow the classification 
of NSCLCs as AdenoCarcinoma (AC), Squamous Cell Carcinoma (SCC) or Large Cell 
Carcinoma (LCC). In particular Thyroid Transcription Factor-1 (TTF-1) positivity by IHC is 
typical of ACs, p40 or p63 IHC positivity is related to SCCs and no staining pattern is linked 
to LCCs. Among NSCLCs, AC represents the histotype with the highest rate (60%). SCC and 
LCC constitute 25% and 15% of all NSCLCs, respectively (Herbst RS et al, 2008). During the 
last 25 years, the distribution of histological types of NSCLC has changed: in the USA, SCC, 
which was predominant, decreased and AC has increased in both genders becoming, 
nowadays, the most diffuse histotype. In Europe, similar trends have occurred in men, while, 
in women, both SCC and AC are still increasing (Forman D et al, 2013). The new 2015 WHO 
classification recommends to test by IHC not only tumor resection but also biopsies, with a 
limited panel of IHC assays (e.g. only TTF-1 and p40 test). 
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Concerning classification, on the basis of morphological features, pathologists are used to 
define lung cancer with a grade that describes the differentiation of the tumor: G1 indicates a 
well differentiated cancer, G2 a moderately differentiated cancer, G3 a poorly differentiated 
cancer, G4 an undifferentiated cancer and GX a cancer in which grade of differentiation 
cannot be assessed. The criteria revised in 2015 advise to exclude grade classification in 
biopsies. Another way to characterize lung cancer is the TNM classification, where T 
indicates the extent of the primary tumor, N the absence or presence and the extent of regional 
lymph nodes metastases and M the absence or presence of distant metastases (Travis WD et 
al, 2004; Goldstraw P et al, 2015; TNM classification for lung cancer proposed by the 
IASLC: 8th edition). The addition of numbers to these letters indicates the extent of the 
malignant disease (Table 1.1, 1.2 and 1.3).  
 
T 
T0 No primary tumor 
Tis Carcinoma in situ (SCC or AC) 
TX T status cannot be assessed 
T1 
Tumor ≤ 3cm 
T1a(mi) Minimally invasive Adenocarcinoma 
T1aSS Superficially spreading tumor in central airways 
T1a≤1 Tumor ≤ 1cm 
T1b>1-2 Tumor > 1cm but  ≤ 2cm 
T1c>2-3 Tumor > 2cm but  ≤ 3cm 
T2 
Tumor > 3cm but  ≤ 5cm 
T2Visc Pl Tumor involving visceral pleura 
T2Centr Tumor involving main bronchus (not carina), atelectasis to hilum 
T2a>3-4 Tumor > 3cm but  ≤ 4cm 
T2b>4-5 Tumor > 4cm but  ≤ 5cm 
T3 
T3>5-7 Tumor extension  > 5cm but  ≤ 7cm 
T3Inv tumor invading chest wall, pericardium, phrenic nerve 
T3Satell tumor invading separate tumor nodules in the same lobe 
T3>7 Tumor > 7cm 
T4 
T4Inv 
Tumor invading mediastinum, diaphragm, heart, great vessels, recurrent 
laryngeal nerve, carina, trachea, esophagus, spine 
T4Ipsi Nod Tumor nodules in a different ipsilateral lobe 
 
Table 1.1: Definitions for T descriptor (Detterbeck FC et al, 2017). 
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Table 1.2: Definitions for N descriptor (Detterbeck FC et al, 2017). 
 
 
 
Table 1.3: Definitions for M descriptor (Detterbeck FC et al, 2017). 
 
 
Each patient can be described by two classifications, the first one is a pretreatment clinical 
classification (cTNM) and the second one is a postsurgical histopathological classification 
(pTNM) (Goldstraw P et al, 2015; TNM classification for lung cancer proposed by the 
IASLC: 8th edition). 
Oncologists can define lung cancer stage applying the TNM classification (Table 1.1, 1.2 and 
1.3), indeed the combination between T, N and M descriptors permits the classification of 
lung tumors in Stage 0, Stage I (i.e. IA; IB), Stage II (i.e. IIA; IIB), Stage III (i.e. IIIA; IIIB; 
IIIC) and Stage IV (i.e. IV; IVA and IVB) (Detterbeck FC et al, 2017). 
 
 
1.3) AC: general characteristics and molecular data 
 
As aforementioned, AC is the most common histotype among lung cancers. Patients affected 
by this histotype are frequently women and Asian. Indeed, AC represents 42% of lung cancers 
in women and 28% in men. ACs are anatomically characterized by neoplastic cells producing 
N 
N0 No regional node metastasis 
NX N status cannot be assessed 
N1 Metastasis in ipsilateral pulmonary or hilar nodes 
N2 Metastasis in ipsilateral mediastinal/subcranial nodes 
N3 Metastasis in contralateral mediastinal/hilar or supraclavicular nodes 
M 
M0 No distant metastasis 
M1 
Tumor with distant metastasis(es) 
M1aPl Dissem Malignant pleural/pericardial effusion 
M1aContr Nod Pleural/pericardial nodules or separate tumor nodules in a contralateral lobe 
M1bSingle Single extrathoracic metastasis 
M1cMulti Multiple extrathoracic metastases (one or more organs) 
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mucus and organized in different structures, such as beads, ducts or solid clumps (Figure 1.1). 
Usually, this histotype is identified as a grey nodule with irregular borders that blend in the 
lung parenchyma located near visceral pleura (Corrin B, 2000). ACs patterns could be clearly 
present or not clearly present but they can be supported by special stains analyses (e.g. TTF-1 
IHC positivity) (Figure 1.1B).  
 
 
 
Figure 1.1: A) Hematoxylin and eosin (HE) staining of lung AC cells organized in an acinar 
structure. The cells exhibit hyperchromatic nuclei in a fibroblastic stroma. B) Positive 
immunohistochemical staining for TTF-1 in AC tissue (IARC/WHO classification; 
https://ww.iarc.fr/). 
 
 
AC frequently leads to the development of distant metastases in liver, bone, central nervous 
system, adrenal glands through blood, and in loco regional lymph nodes through the 
lymphatic system (Corrin B, 2000). As aforementioned, AC histotype is typically identified 
by the histochemical marker TTF-1.  
In lung cancers, the most important molecular markers are the following genes: EGFR 
(Epidermal Growth Factor Receptor), KRAS (Kirsten Rat sarcoma viral oncogene homolog), 
BRAF, ALK (Anaplastic Lymphoma receptor tyrosine Kinase), ROS1 and HER2 o ErbB2 
(Human Epidermal growth factor Receptor 2) (Herbst RS and Lippman AM, 2007; Bos M et 
al, 2013; De la Bellacasa PR et al, 2013) (Figure 1.2). 
 
 
 
A B 
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Figure 1.2: Pie chart representing the frequency of oncogenic alterations in lung AC (Gerber DE 
et al, 2014). 
 
 
1.3.1 EGFR 
The EGFR gene is located on the short arm of chromosome 7 (region 7p11) and encodes for a 
tyrosine kinase (TK) receptor of 170kDa. This transmembrane glycoprotein binds to the 
epidermal growth factor (EGF) and the binding induces receptor dimerization and tyrosine 
autophosphorylation leading to the creation of specific binding sites for the protein members 
of RAS-RAF-MEK or PI3K-Akt-mTOR pathways (Mitsudomi T and Yatabe Y, 2010) 
(Figure 1.3 and 1.4).  
 
 
 
Figure 1.3: EGFR protein: A) Structure; B) Activation; C) Dimerization by ligand binding 
(Mitsudomi T and Yatabe Y, 2010). Abbreviations: CR, cysteine-rich domain; EGF, epidermal growth 
factor; ex, exon; L, large EGF binding domain. 
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Figure 1.4:Picture of a direct immunofluorescence experiment conducted on a lung cell line and 
showing the transmembrane localization of EGFR receptor. In this figure EGFR receptor specific 
antibodies are targeted with green signal, cells nuclei are colored with DAPI (4',6-diamidino-2-
phenylindole) staining (blue) and microtubules are colored with the binding of a specific antibody 
against tubulin (red) (The Human Protein Atlas).  
 
 
Therefore, ligand binding to the receptor activates one of the two aforementioned pathways 
related to transcriptional activation of genes involved in cellular proliferation, differentiation, 
metastasis, angiogenesis and programmed cell-death (Koudelakova V et al, 2013).  
EGFR activating alterations are observed in 15-20% of NSCLC among Caucasian patients 
and in 40% of NSCLC patients among Asians (Banno E et al, 2016; Ko B. et al, 2017). 
Mutations in EGFR are present in 20% of Caucasian patients with AC histotype and are 
represented by alterations occurring in exons 18, 19, 20 and 21 (Gerber DE et al, 2014). The 
most widespread alterations of EGFR in lung cancers are point mutations (e.g. G719C, 
G719S, G719A in exon 18; T790M in exon 20; L858R, L861Q, L861R in exon 21), deletions 
(e.g. E746_A750del, L747_T751del and L747_P753del in exon 19) and insertions (e.g. 
D770_N771insNPG, D770_N771insSVQ and D770_N771insG in exon 20). Exons 19 and 21 
mutations account for 85-90% of all the EGFR mutated cases and the incidence of de novo 
exon 20 insertions is 3.4% (Rosell R et al, 2012; Noronha V et al, 2017). EGFR mutations 
mainly occur in women, non-smokers of Asian origin. 
 
1.3.2 KRAS 
The KRAS gene is located on the short arm of chromosome 12 (region 12p12) and encodes for 
a GTPase protein of 21kDa, involved in the intracellular transductional pathways regulated by 
TK receptors which are related to apoptosis, cell growth and proliferation. KRAS protein 
activity is influenced by the exchange between GDP (guanosine triphosphate) and GTP 
(guanosine triphosphate). The binding of GTP to KRAS leads to the activation of this protein 
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and the recruitment of RAF proteins. KRAS binding to RAF leads to the phosphorylation of 
MAP2K and MAP2K-2 and, consequently, to the activation of MAPK (Mitogen-Activated 
Protein Kinase).  
In lung cancer, KRAS alterations are represented by point mutations, mainly occurring in exon 
2 (codons 12-13) and rarely in exon 3 (codons 59-61) or 4 (codon 146) (Koudelakova V et al, 
2013). They are identified in 10-40% of AC patients and are generally mutually exclusive 
with EGFR genetic alterations (Gerber DE et al, 2014). KRAS mutation occurs predominantly 
in smoker patients.  
 
1.3.3 BRAF 
BRAF gene is situated on the long arm of chromosome 7 (region 7q34) and encodes for a 
protein of 94 kDa belonging to the RAF family of serine/threonine protein kinases. This 
protein plays an important role in regulating the MAPK signaling pathway, which affects cell 
division, differentiation, and secretion.  
In lung cancer, BRAF alterations are point mutations located in exons 11-15 and they have 
been found in 2-4% of ACs (Herbst RS et al, 2008; Michaloglou C et al, 2008; Gerber DE et 
al, 2014). Half of them are represented by the V600E change (exon 15). The remaining 50% 
of mutations are mainly G469A and G466V (40%) in exon 11 and D594G (10%) in exon 15 
(Michaloglou C et al, 2008). BRAF mutations mainly occur in heavy smokers. 
 
1.3.4 ALK 
ALK gene is located on the short arm of chromosome 2 (region 2p23) and encodes for a TK 
receptor of 140kDa which belongs to the insulin receptor superfamily. It plays an important 
role in the development of the brain and exerts its effects on specific neurons in the nervous 
system.  
This gene has been found to be rearranged in NSCLC and in a series of cancers, including 
anaplastic large cell lymphomas and neuroblastoma (Rikova K et al, 2007). Chromosomal 
rearrangements are the most common genetic alterations in ALK gene, resulting in creation of 
multiple fusion genes essential for cancer development. The most common rearrangement is 
the EML4/ALK (Echinoderm microtubule-associated protein-like 4/ALK) represented by a 
paracentric inversion between these two genes, both situated on chromosome 2. This 
inversion characterizes 3-7% of AC cases and it leads to the chimeric EML4-ALK gene. The 
EML4-ALK gene is the result of a chromosome rearrangement between the DNA sequence 
coding for N-terminal portion of EML4 and the sequence coding for ALK TK domain. 
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Rearrangements involving EML4 and ALK genes are characterized by a huge number of 
variants; literature reports at least 15 variants of ALK inversion, with variant one (exons 1-13), 
variant two (exons 1-20) and variant three (exons 1-6) being the most common (Figure 1.5). 
ALK gene can be characterized also by rare rearrangements (e.g. ALK/KIF5B, ALK/TGF, 
ALK/KLC1 and ALK/HIP1), representing only 1% of the rearranged cases (Takeuchi T et al, 
2006; Rikova K et al, 2007) (Figure 1.5). ALK rearrangements are usually detected in never or 
light smokers, non-Asians and young women. 
 
 
 
Figure 1.5: Chart representing some ALK fusion variants. This figure reports different variants of 
ALK/EML4 rearrangements and the rare fusions of ALK with other genes (e.g. KIF5B, TFG) (My 
Cancer Genome website). Abbreviations: V, variant. 
 
 
1.3.5 ROS1 
ROS1 gene is situated on the long arm of chromosome 6 (region 6q21-22) and encodes for a 
TK receptor belonging to the insulin receptor superfamily whose molecular weight is 82kDa. 
ROS1 plays an important role in the regulation of PI3K-Akt-mTOR and RAS-RAF-MAPK 
pathways, which are related to cell proliferation and differentiation. ROS1 alterations in 
cancers are generally characterized by rearrangements and in lung cancer the most common 
ones are ROS1/FIG, ROS1/SLC34A2, ROS1/CD74, ROS1/EZR, ROS1/LRIG3, ROS1/SDC4 
and ROS1/TPM3, cumulatively identified in about 1% of all NSCLC cases and in 1-3% of AC 
subtype (Gerber DE et al, 2014). These alterations are mutually exclusive with ALK 
rearrangements and are associated with young, female patients (Yoshida A et al, 2013). 
 
1.3.6 HER2 
The HER2 gene is situated on the long arm of chromosome 7 (region 17q21-17q22) and 
encodes for a protein belonging to the EGFR family. This protein seems not to have a ligand 
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binding domain and therefore should not bind any growth factor, indeed an HER2 growth 
factor has not been found yet. However, it tightly binds other ligand-bound EGF receptor 
family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-
mediated activation of downstream signaling pathways, such as those involving RAS-RAF-
MEK, PI3K-Akt-mTOR and JAK-STAT axis. The activation of these pathways leads to the 
promotion of cellular proliferation and angiogenesis (Cappuzzo F et al, 2005; Garrido Castro 
AC and Felip E, 2013; Martin V et al, 2013).  
In primary lung cancer, HER2 alterations are mainly represented by mutations (usually 
characterized by small nucleotide insertions) occurring in exon 20 and identified in 1-3% of 
all the ACs (Gerber DE et al, 2014). HER2 mutations, like EGFR, mainly occur in non-
smokers women.  
 
 
1.4) Therapies 
 
Surgical resection is the first approach in patients affected by early staged AC; in case of 
advanced stage, tumor resection must be combined with chemotherapy. 
Currently, the most diffused treatment for lung cancer is platinum (cis-Pt or carboPt)-based 
doublet chemotherapy from four to six cycles. The doublet is characterized by the 
combination of Pt and a couple of cytotoxic molecules (Gemcitabine, Paclitaxel, Docetaxel, 
Vinorelbine or Pemetrexed) (Cufer T et al, 2013; Shepherd FA et al, 2013). Several studies 
have compared Pt-based doublets containing these cytotoxic molecules and survival rates 
have been similar in all the trials. In 2008, the administration of Pt doublet chemotherapy 
brought to the reduction of the mortality rate of nearly 23% (Cufer T et al, 2013). A clinical 
trial of 2009 showed that, in patients treated with four cycles of chemotherapy, without 
progression, a maintenance cure with a single cytotoxic molecule leads to the increase of OS 
and Progression Free Survival (PFS) (Ciuleanu T et al 2009). Recent data demonstrate that 
the administration of bevacizumab (Avastin
®
; F. Hoffmann-La Roche Ltd, Basel, CH), a 
monoclonal antibody against the VEGF (Vascular Endothelial Growth Factor), in second and 
third line and in combination with Pt doublet chemotherapy leads to an advantage in lung 
cancer treatment. Indeed, the ECOG 4599 trial showed that bevacizumab administered in 
combination with carboPt and Paclitaxel may increase the PFS and OS of nearly two months 
(Sandler A et al, 2006; Zarogoulidis K et al, 2013). 
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Radiotherapy can also be recommended before surgery to reduce tumor dimensions and after 
surgery to reduce the risk of local relapse (Shepherd FA et al, 2013). 
 
 
1.5) Targeted therapies 
 
Chemotherapies are limited by their lack of specificity and by frequent and potentially severe 
dose-limiting toxicities. Therefore, there is an urgent need for more effective, better-tolerated 
treatments that specifically target the process pivotal to tumorigenesis and metastasis. 
Consequently, in recent years there was a rapid progress in the development of new treatment 
strategies for advanced NSCLC, in particular with the introduction of molecular targeted 
therapies (i.e. chemotherapies able to specifically target molecular alterations occurring in a 
given tumour) (Kaneda H et al, 2013). The most diffused targeted drugs in lung cancers are 
the small-molecule tyrosine kinase inhibitors (TKIs) acting against EGFR and ALK 
alterations. However last years have seen also the birth of phase I, II and III studies based on 
targeted therapies against rare AC mutations (e.g. alterations in ROS1, HER2, BRAF and 
KRAS) (Tsao AS et al, 2016) (Figure 1.6).  
 
 
 
Figure 1.6: Pie chart representing the frequency of molecular alterations in various driver 
oncogenes in lung AC and the current available drugs against these oncogenic proteins (Tsao AS 
et al, 2016). 
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1.5.1 EGFR-targeted therapies 
Last years have seen the introduction of targeted therapies against EGFR, the most effective 
are the TKIs. These drugs specifically target EGFR in lung ACs characterized by activating 
alterations in this gene.  
Other targeted therapies available are, beside EGFR TKIs, cetuximab (Erbitux
®
; Bristol-
Myers Squibb, New York, USA) and panitumumab (Vectibix
®
; AMGEN, CA, USA), two 
anti-EGFR antibodies directed against EGFR receptor binding domain. However trials 
demonstrated that patients affected by lung cancer do not show a clear response to the 
treatment with anti-EGFR antibodies (Mukohara T et al, 2005; Rossi A et al, 2008). 
Consequently, on these bases, molecular therapies against EGFR in lung ACs are mainly 
characterized by TKIs. In 2009, the IPASS study demonstrated that in patients with EGFR 
mutations the treatment with TKIs gives a better response compared to standard 
chemotherapy regimens (Mok TS et al, 2009). Current guidelines, such as those of the 
National Comprehensive Cancer Network (NCCN) and the European Society for Medical 
Oncology, recommend the testing of EGFR mutations in all patients with advanced non-
squamous NSCLC before initiation of first-line therapy. This recommendation is based on 
phase III randomized controlled trials demonstrating improvements in Response rates (RR) 
and PFS when EGFR mutated patients are treated with TKIs, compared to chemotherapy 
administration (Batson S et al, 2017).  
To date, three generations of TKIs against EGFR have been developed and approved for the 
treatment of mutated patients. The first generation (1
st
G) TKIs, gefitinib (Iressa
®
, ZD1839; 
AstraZeneca, Cambridge, UK) and erlotinib (Tarceva
®
; Roche), are small molecules acting as 
reversible inhibitors of EGFR through their competitive binding to the TK intracellular 
domain in proximity of the ATP/Mg
2+
(adenosine triphosphate/magnesium
2+
) binding site. 
This binding inhibits the TK activity enhanced by activating mutations of EGFR. In 2015, in 
the USA, gefitinib was finally introduced as first-line therapy for patients harbouring 
mutations in EGFR, after a phase IV study demonstrating an objective response rate (ORR) of 
70%, a medium PFS of 9.7 months and a medium OS of 19 months (Douillard J et al, 2014). 
Concerning erlotinib, in 2012 the EURTAC randomised phase III trial demonstrated that this 
TKI gives a better OS versus standard chemotherapy as first-line treatment for European 
patients with EGFR mutations (Rosell R et al, 2012). 
On these bases, in 2013, in Europe and USA erlotinib was approved as first-line therapy in the 
metastatic setting after the results of EURTAC trial (Rosell R et al, 2012). 
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The most diffused genetic alterations in EGFR correlated with sensitivity to 1
st
G TKIs are all 
the deletions occurring in exon 19 (e.g. E746_A750del), point mutations in exon 21 (e.g. 
L858R, L861R and L861Q), exon 18 (e.g. G719A, G719C and G719S) and exon 20 (e.g. 
V765A, T783A) (Banno E et al, 2016; Saad N et al, 2017). There is little evidence whether 
different deletions in exon 19 are associated with different therapeutic response and clinical 
outcomes under TKI therapies. In preliminary studies the TKIs versus EGFR seem to be more 
effective against NSCLCs with E746del than those with E747del (Lee VH et al, 2013; 
Kaneda T et al, 2014). The efficacy of 1
st
G TKI in patients harbouring the S768I mutation (in 
exon 20) is till debated (Yang JC et al, 2015; Banno E et al, 2016; Chen K et al, 2017). On the 
contrary, all the rearrangements (e.g. D770_N771insNPG, D770_N771insSVQ, 
D770_N771insG) and some point mutations (T790M, V796L, N771T) in exon 20 are 
associated with resistance to 1
st
G TKIs (Figure 1.7). Last alterations are classified as primary 
resistance, happening before the therapy. Furthermore there are also mechanisms of secondary 
resistance happening after the administration of the treatment. Indeed, despite the fact that 60-
80% of patients show an initial response to EGFR TKIs, in the majority of cases there is the 
development of disease progression related to the acquired resistance happening within one to 
two years after treatment initiation (Jänne PA et al, 2015). 
 
 
 
Figure 1.7: EGFR mutations associated with response or resistance to gefitinib and erlotinib in 
lung AC (Sharma VS et al, 2007). 
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The most common molecular mechanism inducing secondary resistance is the mutation 
T790M in exon 20. Indeed, T790M is found in 50-70% of ACs resistant to TKIs (Murray S et 
al, 2012; Santarpia M et al, 2017). Other mechanisms of resistance are: HER2 and MET gene 
amplification, transformation to SCC, PIK3CA gene mutation and activating mutations in 
RAS or BRAF genes; representing respectively 12-15%, 5-11%, 5%, 1% and 0.5 % of resistant 
cases (Yun C-H et al, 2008; Takezawa K et al, 2012) (Figure 1.8).  
 
 
 
Figure 1.8: Mechanisms of resistance to EGFR TKIs. EGFR T790M mutation is the major cause of 
TKIs resistance but many other mechanisms could be present even if in minor rates (Takezawa K et al, 
2012). 
 
 
To overcome TKIs resistance, some trials have studied the efficacy of the treatment with 
second generation (2
nd
G) inhibitors; such as afatinib (Gilotrif
®
 or Giotrif
®
; Boehringer 
Ingelheim, Germany), dacomitinib (PF-00299804; Pfizer, New York, USA) and neratinib 
(HKI-272; Puma Biotechnology, Los Angeles, CA, USA) (Kaneda H et al, 2013; Saad N et 
al, 2017). Second generation TKIs can overcome resistance to 1
st
G TKIs by an irreversible 
binding to EGFR TK domain; in addition, uncommon EGFR mutations (i.e. alterations 
representing a little part of EGFR mutated patients) like L861Q, S768I and mutations in 
EGFR exon 18 are more sensitive to 2
nd
G TKIs than 1
st
G TKIs (Yang JC et al, 2015). 
Afatinib has been studied and compared to the other treatments (1
st
G TKIs or different 
chemotherapy regiments) in the LUX-Lung trials and, after the demonstration of its efficacy, 
in 2013 it was approved by the U.S. Food and Drug Administration (FDA) as first-line 
treatment for metastatic EGFR-mutated NSCLC (Sequist LV et al, 2013; Wu Y-L et al, 2014; 
Ko B et al, 2017). Recent studies report that 2
nd
G TKIs efficacy can be compromised by 
acquired mutation in the cysteine 797 residue (C797) of EGFR receptor, the position of the 
irreversible covalent bond between these molecular drugs and EGFR (Chong CR et al, 2013; 
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Gainor JF et al, 2013). In addition, 2
nd
G TKIs have a limited effect against T790M because 
their high rate of toxicities limit the availability to administer doses sufficient to effectively 
inhibit this mutation (Santarpia M et al, 2017). 
To solve this problem, there was the introduction of third generation (3
rd
G) TKIs, mutant 
selective irreversible inhibitors. Third generation TKIs, such as osimertinib (Tagrisso
®
, 
AZD9291; Astra Zeneca) and rociletinib (CO-1686; Clovis Oncology, CO, USA) are 
effective in patients with NSCLC harbouring specific mutations. Osimertinib is an irreversible 
TKI targeting the T790M mutation with a covalent binding to C797 in the EGFR ATP 
binding site. Phase I AURA trial tested the safety and efficacy of osimertinib as second line in 
NSCLC patients showing progression after previous treatment with EGFR TKI administration 
(Janne PA et al, 2015). This study demonstrated that, in the subgroup of T790M-positive 
patients, osimertinib showed high activity with an ORR of 61% and a median PFS of 9.6 
months. In comparison, in patients with no detectable EGFR T790M, the ORR was 21% and 
PFS was 2.8 months. Subsequently, the Phase II AURA trial, testing advanced or metastatic 
NSCLC patients with T790M, confirmed the high activity of osimertinib at the dose of 80 mg 
daily, single administration (Santarpia et al, 2017). On these bases, in 2015, the FDA 
approved the treatment with osimertinib in patients with a T790M-positive NSCLC whose 
disease had progressed after the administration of other TKIs. The approval by European 
Commission was received in 2016 (Mitsudomi T et al, 2015). 
Rociletinib is another covalent inhibitor of EGFR mutations that does not affect exon 20 
insertions but inhibits exon 19 deletions, L858R, and T790M mutations. Patients enrollment 
for ongoing rociletinib studies, including the Phase III TIGER-3 trial, is finished but the 
manufacturer has withdrawn its application for regulatory approval by FDA and EMA 
(European Medicines Agency). Rociletinib and others 3
rd
G TKIs are still object of severe 
clinical trials. In patients showing disease progression and treated with 1
st
G or 2
nd
G TKIs, the 
NCCN panel recommends to continue the same TKI with local treatment if there is local 
progression and to add chemotherapy to TKI or switch to 3
rd
G TKIs in case of T790M 
mutation (NCCN website: http://www.nccn.org/). 
The efficacy of 3
rd
G TKIs on T790M-mutant patients can be compromised by new acquired 
mutations, like alterations occurring in the codon 797. Indeed, the most important mutation 
that is correlated with 3
rd
G TKIs resistance is C797S (Figure 1.9). This missense mutation 
brings to the loss of the potential for covalent bond formation in 797 position in the kinase 
binding site (Niederst MJ et al, 2015; Song H-N et al, 2016). A study based on cell lines 
showed that the position of C797S and T790M mutations on EGFR alleles influences the 
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response to molecular targeted therapies. Indeed, when C797S and T790M are in trans (on 
different alleles) there could be a positive response to a combined 1
st
G/3
rd
G TKIs therapy; in 
contrast, when these mutations are in cis (on the same allele) there is no response to any 
EGFR TKI treatment alone and in combination (Niederst MJ et al, 2015). The importance of 
the configuration of C797S and T790M in the response to therapy has been reported also in 
patients (Sacher AG et al, 2016). 
Furthermore, a not negligible fraction of T790M mutated patients may acquire resistance to 
3
rd
G TKIs without harbouring mutations in the codon 797. Ongoing studies havedemonstrated 
that, in these cases, the resistance to 3
rd
G TKIs could be due to other EGFRalterations that 
interfere with the drug binding (e.g. L798I,L718Q, L692V,L844V, E709K;EGFRgene 
amplification), to alterations in other genes that activate by pass pathways (e.g. HER2, MET, 
FGFR1 gene amplification; PIK3CA and RAS/MAPK pathway activating mutations; PTEN 
deletion; IGFBP3 loss) or to phenotypic alterations (e.g. SCLC transformation; epithelial 
mesenchymal transition) (Walter AO et al, 2013; Kim TM et al, 2015; Piotrowska Z et al, 
2015; Planchard D et al, 2015; Chabon JJ et al, 2016; Ortiz-Cuaran S et al, 2016; Park JH et 
al, 2016) (Figure 1.9). In addition, 3
rd
G TKIs resistance could be due to the reduction or 
disappearance of T790M clones determined by the selective pressure caused by the treatment 
with 3
rd
G TKIs (Minari R et al, 2016).  
Osimertinib resistance due to T790M reduction or disappearance and the resistance due to 
alterations in genes of the bypass pathways can be overcome using existing methods like 
exchange to/addition of a 1
st
G TKI or concurrent combination therapy of an inhibiting 
alternative pathway (Uchibori K et al, 2017). 
To date, we have no clinically available strategy to care patients characterized by 
C797S/T790M/activating mutation (triple-mutation). However a study reports that brigatinib 
(AP26113; Ariad Pharmaceuticals, MA, USA), an ALK-TKI in clinical development, could 
have efficacy in the care of triple mutated cases (Uchibori K et al, 2017). Furthermore, the 
efficacy of brigatinib seems to be enhanced markedly by its combination with anti-EGFR 
antibodies (cetuximab and panitumumab) (Uchibori K et al, 2017). In the future, fourth 
generation (4
th
G) TKIs will be developed. Indeed, in 2016 the combination of EAI045 
(Chemscene, New York, USA), an experimental 4
th
G TKI, with cetuximab was effective in 
mouse models of lung cancer driven by EGFR L858R/T790M and by EGFR 
L858R/T790M/C797S (Jia Y et al, 2016).  
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Figure 1.9: Schematic diagram showing sensitivity of cells with primary EGFR TKI-sensitizing 
mutations (in purple) in the presence or absence of the secondary EGFR T790M mutation (in 
turquoise) and with different tertiary mutations (in red) (Ayeni D et al, 2015). Abbreviations: 
TKIs, tyrosine kinase inhibitor. 
 
 
Beside monotherapies based on TKIs administration, recent clinical trials are investigating the 
effect of combination therapies, like the aforementioned brigatinib plus anti-EGFR antibodies 
treatment, for highly resistant patients. Recently, BELIEF Phase II trial investigated the 
combination of erlotinib plus bevacizumab and demonstrated a prolonged medium PFS of 16 
months compared with the 9.7 months for erlotinib monotherapy in T790M mutated patients 
(Seto T et al, 2014). In support of these data, preclinical evidence suggests that erlotinib 
resistance may be associated with a rise of VEGF levels. In addition, a study assessed 
gefitinib plus chemotherapy and demonstrated an advantage for combination therapy over 
gefitinib monotherapy in EGFR mutant cases (Batson S et al, 2017). To conclude, in another 
Phase II trial the combination of afatinib with cetuximab resulted in a RR of 30% and a 
medium PFS of 4.7 months in heavily pretreated patients (Janjigian YY et al, 2014). 
 
1.5.2 ALK and ROS1-targeted therapies 
Other molecular therapies for NSCLC treatment are the TKIs acting in ALK-rearranged 
patients. The first targeted therapy developed against ALK alterations was crizotinib 
(Xalkori®; Pfizer), a dual ALK and MET TKI able to inhibit ALK through the interaction 
with its ATP binding site, leading to the block of downstream molecular pathways (Bergethon 
K et al, 2012). PROFILE 1001, a phase I trial testing crizotinib in advanced-stage ALK 
positive NSCLC, demonstrated an ORR equal to 57% and a PFS equal to 72%. In addition, 
PROFILE 1005, a phase II study that enrolled patients with advanced, previously treated, 
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ALK-positive NSCLC, showed an ORR of 60% and a PFS of 8.1 months after crizotinib 
administration (Kim DW et al, 2012). Later, two phase III trials, PROFILE 1007 and 
PROFILE 1014 demonstrated the better efficacy of crizotinib compared to chemotherapy in 
patients with ALK rearrangements. More in detail, crizotinib administration showed a PFS of 
7.7 months compared to 3 months in patients treated with standard chemotherapy in 
PROFILE 1007, and a PFS of 10.9 months compared to the 7 months of the chemotherapy 
arm in PROFILE 1014 (Leprieur EG et al, 2016; Novello S et al, 2016). 
Crizotinib was approved in 2011 by FDA and in 2012 by EMA for the clinical care of 
previously treated ALK-positive NSCLC. In 2013, crizotinib received approval by FDA also 
as first-line treatment for patients with ALK-positive NSCLC and in 2015 the EMA approved 
the same indication. 
Unluckily patients treated with crizotinib can experience disease progression after 8-12 
months through primary or acquired resistance. Various mechanism of resistance have been 
identified, including secondary ALK mutations, ALK fusion gene amplifications and 
alterations in alternative signaling pathways (e.g. KIT amplification, EGFR or KRAS 
mutations) (Doebele RC et al, 2012; Katayama R et al, 2012). In 30% of cases, the resistance 
to crizotinib is associated with a secondary mutation in the kinase domain of ALK that 
interferes with the drug binding or ATP affinity (Passaro A et al, 2016). Several resistance 
ALK mutations have been identified but the most common are L1196M and G1269. Other, 
rarer ALK mutations leading to crizotinib resistance are: C1156Y, F1174L, L1152R, S1206Y, 
I1171T, V1180L, D1203N (Toyokawa G and Seto T, 2015).  
Recently, new 2
nd
G ALK TKIs have been developed to overcome resistance to crizotinib, 
such as ceritinib (Zykadia
®
; Novartis, CH and USA) and alectinib (Alecensa
®
; Roche).  
In preclinical models, ceritinib is nearly twenty times more efficient than crizotinib in both 
crizotinib-sensitive and crizotinib-resistant tumors. Ceritinib was evaluated in ASCEND-1 
trial, a phase I trial including patients with ALK-positive NSCLC, in both ALK inhibitor naïve 
and ALK inhibitor pretreated cases. The ORR was 72% in ALK inhibitor naïve patients 
compared with 56% in crizotinib pretreated patients, in addition the mean PFS was 18.4 
months and 6.9 months respectively (Kim DW et al, 2016). In 2014 on these results FDA 
approved ceritinib for patients with advanced or metastatic ALK-positive NSCLC progressing 
to crizotinib. 
Alectinib is another ALK TKI developed to overcome crizotinib resistance. This drug is 
efficient in crizotinib naïve and in crizotinib-resistant ALK-positive NSCLC, as recently 
demonstrated. Two phase I/II trials were conducted in order to evaluate the efficacy and 
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safety of this drug. The first one, named AF-001JP, was conducted in Japan on ALK-positive, 
crizotinib naïve NSCLC. AF-001JP in phase II showed an ORR of 93.5% and a PFS at twelve 
months of 83%. The second trial, AF-002JG, was conducted in USA on patients with ALK-
positive NSCLC who progressed on or were intolerant to crizotinib. This study in phase II 
demonstrated an ORR to alectinib equal to 55%. Furthermore, ALEX and J-ALEX trials 
demonstrated the superiority of alectinib over crizotinib as first-line treatment in patients with 
ALK-positive advanced NSCLC and not treated with ALK inhibitor (Ou SH et al, 2016; Shaw 
AT et al, 2016; Nokihara et al, 2016). On these bases, alectinib was approved by FDA in 2015 
for the treatment of patients with advanced ALK-positive NSCLC whose disease worsened 
after, or who could not tolerate, the administration of crizotinib. In addition, it got a 
conditional approval by the EMA in February 2017 for the same indication. This means that 
additional studies are awaited to confirm a positive benefit-risk ratio. 
Some patients can develop secondary ALK mutations bringing to resistance to ceritinib (e.g. 
G1202R, F1174C and F1174V) or to alectinib (e.g. G1202R, V1180L, I1171T and I1171N) 
(Passaro A et al, 2016). In particular, the G1202R mutation increases significantly after 
treatment with 2
nd
G ALK TKIs and seems to induce resistance to both crizotinib and 2
nd
G 
ALK TKIs. Moreover, mutations affecting the codon 1171 bring to resistance to alectinib but 
are sensitive to ceritinib.  
In order to overcome 2
nd
G ALK TKI resistance, last year has seen the development of 3
rd
G 
ALK TKIs: brigatinib (Alunbrig
TM
, AP26113; ARIAD) and lorlatinib (PF-6463922; Pfizer).  
Brigatinib overcomes crizotinib and 2
nd
G ALK TKIs resistance showing activity especially 
against L1196M and G1202R mutations. In May 2017, the FDA approved brigatinib for 
patients with metastatic NSCLC characterized by alterations in ALK gene and whose cancer 
has progressed during their initial therapy (Passaro A et al, 2016). 
Lorlatinib is a 3
rd
G ALK TKI that is nearly 10-fold more effective against wild-type (wt) 
EML4-ALK and nearly 40-fold more active against the L1196M point mutation compared to 
crizotinib. Preliminary data show an ORR of 50% in patients with ALK rearrangement treated 
with this drug (Passaro A et al, 2016).  
Some ALK TKIs are useful against ROS1 alteration as well: indeed, patients harbouring 
ROS1 rearrangement and treated with crizotinib demonstrated an ORR of 57% and a disease 
control rate (DCR) of 80% after two months (Shaw AT et al, 2016). Crizotinib is a more 
potent inhibitor of ROS1 than of ALK, leading to more effective target inhibition and more 
durable response (Gainor JF and Shaw AT, 2013; Shaw AT et al, 2016). In 2016, the FDA 
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approved crizotinib for the treatment of patients with ROS1-positive, advanced NSCLC (Zhao 
Z et al, 2017).  
Furthermore, ceritinib, brigatinib and lorlatinib can also be used against ROS1 alterations and 
could be useful when a secondary resistance to 1
st
G or 2
nd
G ROS1 TKIs appears (Tsao  AS et 
al, 2016). In addition, MET inhibitors could be effective against ROS1 rearrangements as 
well: this seems to be the case of foretinib (GSK1363089, Exelixis) and cabozantinib 
(Cabometyx
®
, Exelixis), that are currently studied in undergoing clinical trials for the 
treatment of prostate, bladder, ovarian, brain, melanoma, breast, pancreatic, hepatocellular 
and lung cancers (Davare MA et al, 2013; Gainor JF and Shaw AT, 2013). 
 
1.5.3 HER2, BRAF and KRAS-targeted therapies  
Besides EGFR and ALK TKIs, researchers are going to investigate if there could be other 
molecular markers associated with specific targeted therapies that may help the care of 
NSCLC patients. For example, HER2 is an important molecular marker in gastric and breast 
carcinomas. In these cancers, HER2 molecular alterations are associated with sensibility to 
trastuzumab (Herceptin
®
; Genentech, CA, USA), a monoclonal antibody that inhibits HER2 
through the binding of the extracellular receptor domain. After the discovery of trastuzumab, 
a plethora of clinical trials demonstrated that a novel antibody–drug conjugate named 
trastuzumab emtansine (T-DM1, Kadcyla®; Roche) is more efficient in breast cancer than 
trastuzumab single agent (Hurvitz SA et al, 2013). T-DM1, made of trastuzumab and a potent 
cytotoxic drug connected via a stable linker to the anti-HER2 antibody, was approved by 
FDA on 2013 for breast cancers resistant to trastuzumab and characterized by HER2 gene 
amplification. 
The first clinical trials concerning HER2 targeted therapy in lung cancers were conducted in 
2005 but they did not show a better OS in patients mutated in HER2 and treated with 
trastuzumab (Cappuzzo F et al, 2005).  
However patients with lung cancer and HER2 mutations seem to give response also to the 
TKIs against EGFR (e.g. afatinib, dacomitinib, neratinib). Indeed, in 2015, a group of HER2 
mutated patients extracted from the European EUHER2 cohort and treated with chemotherapy 
and molecular drugs (afatinib, dacomitinib, neratinib or trastuzumab) showed good response 
to targeted therapies. In particular in these HER2 mutant patients, the ORR and PFS after 
trastuzumab administration were 50.9% and 4.8 months respectively (Mazières J et al, 2016).  
To date, in NSCLC, the FDA has not approved yet the targeted therapies against HER2 
because there is the need of more data on this issue. 
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Besides HER2, also BRAF could become another molecular marker in NSCLC. Indeed, 
dabrafenib (Tafinlar
®
; Novartis Pharma) and vemurafenib (Zelboraf
®
; Genentech), are BRAF 
inhibitors that are currently administered to BRAF-mutant melanomas with great success 
(Spagnolo F et al, 2015). In 2011, the FDA approved vemurafenib for the treatment of 
patients with unresectable or metastatic melanoma characterized by BRAF V600E mutation. 
In addition dabrafenib was approved by FDA in 2013 as a single agent for treatment of BRAF 
V600E mutation-positive unresectable or metastatic melanoma. Furthermore, more recently, 
some studies demonstrated that, in melanoma, the combination of dabrafenib and trametinib 
(Mekinist
®
; GlaxoSmithKline, UK and USA), a MEK inhibitor, is more effective in BRAF 
mutated patients compared to the administration of dabrafenib as a single agent (Paik PK et 
al, 2011). In 2014, on these bases, the FDA granted accelerated approval for the combined use 
of trametinib and dabrafenib in order to treat patients with unresectable or metastatic 
melanoma with BRAF V600E or V600K mutation. 
These drugs seem to be associated with an increment of OS in BRAF-mutant NSCLCs as 
well, especially in patients harbouring the V600E mutation. Following these promising 
preliminary data, the efficacy of targeted therapies against BRAF mutation in NSCLC has 
been evaluated in some studies (Paik P K et al, 2011; Gautschi O et al, 2013). Experiments on 
cell lines described that vemurafenib is effective in BRAF V600E mutated cells (HCC364) 
and not effective in non-V600E BRAF mutated cells (H1755), conversely trametinib is 
effective in both conditions. In addition the combination of vemurafenib and trametinib better 
promotes apoptosis than trametinib alone in HCC364 and in H1755 cell lines (Joshi M et al, 
2015). In 2015, a retrospective study on a cohort of patients affected by lung AC, harbouring 
BRAF mutations and extracted from the EURAF cohort, demonstrated an ORR equal to 53% 
and a DCR equal to 85% (Gautschi O et al, 2015). In 2017, the FDA approved the 
combination of dabrafenib and trametinib for the treatment of BRAF V600E mutation-positive 
metastatic NSCLC (National Cancer Institute, National Institutes of Health website: 
https://www.cancer.gov/about-cancer). 
Finally also KRAS could be a potential, new molecular marker in lung AC. The prognostic 
and predictive role of KRAS is controversial, even though the majority of USA studies 
indicate KRAS as a negative predictive marker of response to EGFR TKIs (Eberhard DA et 
al, 2005; Pao W et al, 2005; Massarelli E et al, 2007; Mao C et al, 2010; Garrido-Castro AC 
and Felip E, 2013). In addition, KRAS mutations are a negative predictive marker of response 
to systemic chemotherapy; indeed AC patients characterized by KRAS alterations have a 
worse PFS and a worse RR after chemotherapy administration compared to the cases with a 
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KRAS wt sequence (Wei P et al, 2016). However another work proposed KRAS mutations as a 
factor able to sensitize tumors to pemetrexed (Moran DM et al, 2014).  
Nowadays, no targeted therapies against KRAS have been approved, but in a phase II clinical 
trial of 2013, selumetinib (AZD6244, AstraZeneca), a MEK inhibitor, in combination with 
docetaxel showed preliminary promising results in previously treated advanced NSCLC 
(Jänne PA et al, 2013). On this basis, new ongoing studies are testing other MEK inhibitors 
efficacy in KRAS mutated patients. 
Moreover, KRAS is associated to a worst prognosis. Indeed the majority of studies 
demonstrate that KRAS mutations are an independent predictor of poor prognosis in patients 
with advanced NSCLC (Sun JM et al, 2013). 
 
 
1.6) Liquid biopsies testing 
 
Last years have seen the introduction of liquid biopsies testing, a methodology that is based 
on the analyses of non-solid biological sample (e.g. blood, urine, saliva and cerebral spinal 
fluid). One of the most important applications of liquid biopsies testing is the characterization 
of molecular markers in fluids from patients affected by cancer (Crowley E et al, 2013; Diaz 
LA and Bardelli A, 2014).  
 
1.6.1 Circulating tumor DNA (ctDNA) 
The majority of liquid biospies analyses are conducted on plasma and they are based on the 
characterization of the small portion of cell-free DNA (cfDNA) represented by circulating 
tumor DNA (ctDNA). ctDNA represents less than 0.5% of the cfDNA found in the blood and 
it is released in the blood stream from apoptotic, necrotic or living tumor cells (Malapelle U et 
al, 2016). In addition, it can be produced by circulating tumor cells (CTCs), cells derived from 
the primary tumor or metastasis that can be found in the blood (Cheng F et al, 2016). The 
fragment size of ctDNA is still undetermined because it depends on the cellular process 
causing its release in the circulation. However, it is esteemed that ctDNA size is minor than 
cfDNA dimensions (i.e. around 166bp) (Sholl LM et al, 2016; Sorber L et al, 2016). ctDNA 
half-life is less than two hours and its quantity correlates with tumor volume (Bidard FC et al, 
2014). Many studies highlight an increase in ctDNA levels when the tumor disease progresses 
and a decline in case of resective surgery and/or successful medical therapy (Bettegowda C et 
al, 2014; Diaz LA and Bardelli A, 2014; Pereira E et al, 2015; Sorber L et al, 2016).  
28 
 
The quantity of detectable ctDNA is variable on the basis of the tumor type (Bettegowda C et 
al, 2014). The tumors or metastases producing the highest quantity of ctDNA originate in 
lung, bladder, colorectum, stomach, esophagus and ovaries. On the contrary, tumor and 
metastasis involving brain and bones generally do not produce detectable ctDNA (Bettegowda 
C et al, 2014); because of the presence of the ematoencefalic barrier and the poor 
vascularization of the bones. 
 
1.6.2 Liquid biopsies applications and ctDNA testing 
ctDNA shows the characteristic mutations of the corresponding primary tumor or metastasis 
(Sholl LM et al, 2016). Recently, on this basis,ctDNA analyses brought to the development of 
many diagnostic and treatment applications. Firstly, ctDNA analyses can be used, after and 
during the treatment, to detect the presence of resistance mechanisms, to predict response to 
the therapy or to monitor cancer progression (Figure 1.10). Secondly, ctDNA analyses can 
also be used for early cancer detection, subtyping, prognosis or to detect mutations in patients 
in which tumor biopsy is not feasible (Diaz LA and Bardelli A, 2014; Cheng F et al, 2016).  
 
 
 
Figure 1.10: Detection of tumor-specific DNA mutations in the blood of patients to monitor 
response and relapse to targeted therapies. This figure represents a patient with metastatic 
colorectal cancer. After treatment with anti EGFR monoclonal antibody, the patient experiences a 
clinical response and has a corresponding decrease in APC mutation level, further indicating a 
decrease in tumor burden. Continuous monitoring of plasma DNA shows the emergence of KRAS and 
NRAS mutations and/or MET amplification, indicative of the emergence of multiple different 
resistance clones. Interestingly cfDNA quantity decreases when there is response to therapy and 
increases when clinical resistance happens (Diaz LA and Bardelli A, 2014). Abbreviations: APC, 
adenomatous polyposis coli gene; MET, tyrosine-protein kinase Met; NRAS, neuroblastoma RAS 
viral oncogene homolog. 
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The methodologies for ctDNA testing must be optimized for high sensitivity because the 
genomic material from liquid biopsies is highly fragmented (Sholl LM et al, 2016; Sorber L et 
al, 2016). Several assays with high sensitivity have been developed in order to analyze ctDNA 
for the presence of particular biomarkers. The main techniques are: real-time quantitative 
polymerase chain reaction (real-time qPCR), droplet digital polymerase chain reaction 
(ddPCR), beads emulsion amplification and magnetics quantitative polymerase chain reaction 
(BEAMing qPCR) and next-generation sequencing (NGS) (Sorber L et al, 2016). To date, 
EMA and FDA do not specify which is the better methodology to analyze ctDNA. However, 
the EMA recommends to apply a reliable test with high sensitivity (EMA website: 
http://www.ema.europa.eu).  
Liquid biopsies are less invasive and better reflect tumor heterogeneity than tissue biopsies 
and several studies on mutations detection in coupled peripheral blood and tissues samples 
demonstrated a good correlation of the results obtained with this two kind of materials (Bai H 
et al, 2009; Rosell R et al, 2009; Goto K et al, 2012; Yam I et al, 2012). 
 
1.6.3 ctDNA in lung cancer 
The first studies concerning cfDNA testing in plasma obtained from patients affected by 
tumor were based on the characterization of mutations in lung primary tumor and metastasis 
(Rosell R and Karachaliou N, 2016; Sholl LM et al, 2016). 
Initially, in NSCLC, analyses of plasma were focused on the detection of EGFR mutations 
associated to the resistance to EGFR-targeted TKIs (Rosell R and Karachaliou N, 2016; 
Zheng D et al, 2016; Zhu Y et al, 2017). In particular, the majority of analyses for the 
detection of EGFR TKIs resistance are based on the T790M characterization because 50-60% 
of secondary resistance to TKIs is due to this mutation (Rosell R and Karachaliou N, 2016; 
Zheng D et al, 2016). 
Recent guidelines consider equal the analyses on plasma and on tissue for the detection of the 
T790M and therefore recommend to perform plasma analyses for the screening of this 
mutation before tissue re-biopsy in patients showing relapse after treatment with EGFR TKIs 
(Oxnard GR et al, 2016). In case of detection of the T790M mutation in plasma, the patient 
can be directly adressed to the administration of osimertinib whereas in case of not detection 
of T790M in plasma, clinicians must perform at least a tissue biopsy, on which the molecular 
characterization must be carried on. In case of the presence of T790M mutation in the tissue 
biopsy the patient can be treated with osimertinib, in contrast absence of the T790M mutation 
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also in the tissue specimen addresses the patient to other chemotherapies not involving 
osimertinib. This scheme is reported in Figure 1.11. 
 
  
 
Figure 1.11: Proposed paradigm of plasma genotyping for EGFR T790M mutation in patients 
with acquired resistance to EGFR TKIs. A) In the conventional paradigm, all patients undergo a re-
biopsy for T790M genotyping. B) Recommended new paradigm in which plasma genotyping for 
T790M is used as a screening test before tissue biopsy. Tissue biopsy will be done only in patients 
with no T790M detected in plasma (Oxnard GR et al, 2016). Abbreviations: FDA, food and drug 
administration; TKI, tyrosine kinase inhibitor. 
 
 
As regards the techniques to be used to perform the molecular characterization, in 2016 the 
FDA approved cobas
®
, a real-time polymerase chain reaction (real-time PCR) assay 
developed by Roche, for the analysis of T790M mutation in plasma. However, other 
technologies can be used as well. 
Liquid biopsies are less invasive than tissue biopsies so in the future this feature will permit 
continuative molecular monitoring of lung cancer in order to detect, beside the T790M 
mutation, the appearance of other mutations related to resistance to 1
st
G, 2
nd
G and 3
rd
G EGFR 
TKIs (e.g. C797S) (Rosell R and Karachaliou N, 2016) (Figure 1.12). 
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Figure 1.12: Analyses of ctDNA in liquid biopsies for disease monitoring and for detection of 
mutations involved in TKIs resistance (e.g. T790M and C797S) (Rosell R and Karachaliou N, 
2016). Abbreviations: ctDNA, circulating tumor DNA; EGFR, epidermal growth factor receptor; TKI, 
tyrosine kinase inhibitor. 
 
 
1.7) ROR1 and miR-382 in cancer 
 
The receptor tyrosine kinase-like orphan receptors (ROR1 and ROR2) are transmembrane 
proteins of the receptor TK family. ROR proteins display a common structure:  an 
extracellular domain consisting of an immunoglobulin-like (Ig-like) motif, a Cysteine-Rich 
frizzled Domain (CRD), a Kringle domain and an intracellular domain characterized by a TK 
domain, a Proline-Rich frizzled Domain (PRD) and a Serine/Threonine-Rich Domain 
(S/TRD1 o 2) (Figure 1.13).  
 
 
 
Figure 1.13: Structure of ROR proteins. The extracellular portion contains the Ig-like domain, the 
CRD (Cysteine-Rich frizzled Domain) and the Kringle domain. The intracellular portion contains the 
TK domain (Tyrosine Kinase domain), PRD (Proline-Rich frizzled Domain) and S/TRD 
(Serine/Threonine-Rich Domain) (Rebagay G et al, 2012). 
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ROR proteins are named “orphan receptors” because their endogenous ligand has not been 
discovered yet. However, recent data demonstrate that a putative ligand of ROR1 could be 
WNT, a signaling protein. Indeed, real-time qPCR experiments demonstrate that ROR 
receptors are highly expressed in breast cancer cell lines when also WNT proteins can be 
detected in these cells (Klemm F et al, 2011; Anastas JN et al, 2013). 
ROR receptors are expressed at high levels during embryo development playing an important 
role in skeletal and neural organogenesis but they are not expressed in normal adult tissues 
(Rebagay G et al, 2012). 
ROR1 is upregulated in cancer, in particular in B-cell Chronic Lymphocytic Leukemia (B-
CLL), B-cell Acute Lymphocytic Leukemia (B-ALL) and Mantle Cell Leukemia (MCL) 
(Baskar S et al, 2008; DaneshManesh AH et al, 2008; Shabani M et al, 2008). In 2012, ROR1 
overexpression was observed also in breast cancers by IHC (Zhang S et al, 2012). In addition, 
it was reported that ovarian cancer patients with high expression levels of ROR1 had a higher 
rate of relapse and a shorter mean survival than ovarian cancers patients expressing low or 
negligible levels of ROR1. On these bases, ROR1 may act as a novel prognostic marker in 
ovarian cancers (Dave H et al, 2012; Zhang H et al, 2014; Zhang S et al, 2014; Tan H et al, 
2015). 
ROR1 oncogenic activity is related to its expression in cancer, bringing to the activation of 
PI3K-Akt-mTOR pathway and consequently to the enhancement of cellular migration, 
proliferation and survival. Indeed, literature reports a co-expression between ROR1 
expression and proteins localized in invadopodia and in extracellular matrix (ECM) (Rebagay 
G et al, 2012). 
Recently, one study reported a correlation between ROR1 expression and miR-382, a 
microRNA (miRNA) that is down-regulated in ovarian cancer (Tan H et al, 2016). It was 
found that ROR1 is upregulated in human ovarian cancer tissues whereas miR-382 is 
downregulated. The overexpression of ROR1 in human ovarian cancer cell lines promoted 
cell invasion, while this effect was reversed by overexpression of miR-382. Consequently, 
these results demonstrate that, in ovarian cancer cell lines, miR-382 directly binds ROR1 thus 
inhibiting cell migration and invasion (Tan H et al, 2016).  
 
1.7.1 ROR1 in lung AC 
In lung AC, ROR1 expression was proposed to be associated with TTF-1, an important 
histochemical marker of this histotype. Indeed, two studies have demonstrated that TTF-1 
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may induce ROR1 expression and consequently may activate the pro-survival PI3K-Akt-
mTOR pathway (Yamaguchi T et al, 2012; Zhang S et al, 2012). 
Moreover, it has been demonstrated that the inhibition of ROR1 by silencing RNA (siRNA) 
promotes apoptosis over survival in lung AC cell lines. This response due to ROR1 inhibition 
highlights that its activation in lung AC is related to an increase in tumor cell survival (Figure 
1.14). Interestingly, ROR1 repression inhibits lung AC irrespective of the EGFR status 
(Yamaguchi T et al, 2012). 
In lung tissues, ROR1 seems to mediate survival signals, at least in part, by two mechanisms: 
ROR1 kinase-dependent c-Src mediated signaling and ROR1 kinase-indipendent sustainment 
of EGFR-ERBB3-PI3K signaling (Yamaguchi T et al, 2012). 
In 2012, a study demonstrated that ROR1 is expressed, at protein level by IHC, in about 77% 
of NSCLC (Zhang S et al, 2012). 
 
 
 
Figure 1.14: Proposed model of ROR1 playing a key role in sustaining a favourable balance 
between pro-survival and pro-apoptotic signaling. ROR1 inhibition promotes apoptosis over cell 
survival (Yamaguchi T et al, 2012). 
 
 
1.7.2 ROR1 and targeted therapies 
Recent studies indicate ROR1 as a new potential molecular marker for targeted therapies. 
ROR1 is a good candidate for the formulation of new targeted drugs because it is not 
expressed in adult normal tissues but only in cancer cells. In order to block ROR1 TK 
activity, there are two possible approaches. The first one is represented by the administration 
of monoclonal antibodies able to block the ROR1 binding domain; the second one is the 
treatment with TKIs recognizing ROR1 TK domain (Gentile A et al, 2011; Rebagay G et al, 
2012). The development of TKIs against ROR1 could be promising because literature reports 
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aminoacid substitutions in TK domain that modify ROR1 activity; as a consequence these 
aminoacids could be a good target for the developmentof ROR1 TKIs. Concerning antibodies, 
in vitro experiments have reported that they do not induce the expected apoptosis in 
lymphoma cell lines (Baskar S et al, 2008). Nevertheless, 5 different antibodies tested on 
leukemia cell lines gave better results because they caused cytotoxicity in cancer cell but not 
in normal tissues. Furthermore, cells treated with these monoclonal antibodies showed a better 
response to rituximab (Mabthera
®
; Roche), a targeted therapy against the protein CD20. Both 
treatments are being studied and tests on B-ALL cell lines showed that ROR1 inhibition 
makes cells more sensitive to the treatment with dasatinib (Sprycel
®
; Bristol-Myers Squibb), a 
Src inhibitor (Bicocca VT et al, 2011).  
ROR1 expression can also be predictive of response to chemotherapy or to EGFR TKIs. In 
last years ROR1 expression has been discovered to have a differential effect on the outcome 
to erlotinib and to chemotherapy in EGFR-mutant NSCLC patients. High ROR1 expression 
limits PFS in erlotinib-treated patients with T790M mutations so ROR1 targeted therapies 
could enhance the efficacy of the treatment. In contrast, high ROR1 expression seems to 
confer longer PFS to chemotherapy (Karachaliou N et al, 2014). 
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                                                                      2. AIM 
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The aim of my PhD project is to improve the clinical care of patients affected by lung AC 
enhancing the characterization of molecular markers for targeted therapies and characterizing 
the expression of a new putative marker for targeted therapies, ROR1. Firstly we proposed to 
find new methodologies for the analysis of AC molecular markers that are essential for the 
administration of molecular targeted therapies. The need of new assays is essentially due to 
the particular features of lung AC samples available for molecular diagnosis. Indeed, lung AC 
specimens are generally constituted by poor quantity and poor quality of tumor material. Very 
often only small biopsies are available and, with the current methodology (i.e. direct 
sequencing, DS), it is really difficult to estimate the molecular profile accurately, because the 
sensitivity of these assays is too low. Furthermore, cancer cells are often dispersed in a high 
quantity of normal cells, leading these biopsies cases difficult to be considered representative 
of the tumor. In order to solve all the problems caused by these limits, we decided to test and 
optimize new methodologies with higher sensitivity that will permit to identify a larger 
number of mutations or genetic alterations in patients affected by lung AC. Consequently 
these new assays will permit to enlarge the number of cases that could benefit from targeted 
therapy. The new methodologies that we used are real-time PCR assays named SensiScreen
®
 
(developed by the Danish company PentaBase ApS located in Odense C, Denmark) that are 
based on oligonucleotides with higher specificity, higher sensibility and higher replicability 
than DS for mutations detection in EGFR, KRAS and BRAF genes. Furthermore we proposed 
to test another real-time-based PentaBase kit, focused on the analysis of EGFR T790M 
mutation in blood samples. This test is extremely important because T790M mutation is the 
main reason of secondary resistance to EGFR TKIs and because this assay is specific for 
plasma analyses permitting a less invasive approach, than tissue biopsies, for the 
characterization of this alteration.  
Finally, since about 50% of AC cases display a normal gene status sequences for the 
aforementioned markers, we decided to study ROR1 expression in patients affected by lung 
AC in order to define if it could represent a new target for the formulation of new molecular 
targeted therapies. We proposed to evaluate its expression and to see a potential correlation 
between this marker, the most relevant lung cancers molecular alterations (i.e. EGFR, KRAS, 
BRAF, HER2, ALK and ROS1) and the clinical-pathological features. In addition, we 
evaluated also the association between ROR1 and miR382 expression, a miRNA involved in 
its regulation. This possible new marker could be important for all the patients that cannot be 
treated with the current therapies against alterations in the standard known molecular markers. 
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    3. PATIENTS, MATERIALS AND METHODS
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3.1) Patients 
 
The study population consists of three different cohorts characterized by samples from lung 
AC patients. 
The first cohort includes 471 cases that have been characterized for EGFR, KRAS, BRAF and 
HER2 by DS, for ALK and ROS1 by FISH and for EGFR by SensiScreen
®
, a real-time PCR 
kit developed by our institute and PentaBase ApS. In these samples, the analyses were done 
on formalin-fixed, paraffin-embedded (FFPE) blocks containing small biopsies or resections 
of primary lung AC or lung AC metastases. Pathological data are available for some patients 
of this cohort. 
The second cohort consists of 61 plasma, 5 serum and 39 tissue samples from patients 
affected by lung AC. In some cases plasma and tissue are associated to the primary tumor of 
the same patient. All these cases have been characterized by SensiScreen
®
 liquid biopsy kit 
for T790M mutation in EGFR exon 20 (PentaBase ApS) and by SensiScreen
® 
tissue kit 
(PentaBase ApS) for the other EGFR main mutations. In addition, Ion Torrent
®
 (IOT) 
Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific; Waltham, Massachusetts, 
USA), TheraScreen
® 
(a real-time PCR assay developed by QIAGEN; Chatsworth, CA, USA) 
or DS results were available for some of these patients. To conclude our comparison analyses, 
we tested 42 samples of the second cohort also by cobas
® 
(a real-time PCR assay developed 
by Roche). 
The third cohort includes 102 samples that have been analyzed for EGFR, KRAS, BRAF and 
HER2 by DS; for ALK, ROS1 by FISH; for ROR1 and miR-382 expression by TaqMan real-
time PCR (Applied Biosystems; Foster City, CA, USA). In addition to pathological data in 
this group of patients we have clinical data concerning the type of treatment, the PFS and the 
OS. In this cohort we analyzed the material from FFPE blocks of the primary tumor. 
 
 
3.2) Mutational status of EGFR, KRAS, BRAF and HER2 by DS 
 
Genomic DNA was extracted from six 7-μm FFPE tumor tissue sections using the QIAamp 
Mini kit (QIAGEN), according to the manufacturer’s instructions, and the DNA was 
amplified by Polymerase Chain Reaction (PCR) experiments. The tumor area was selected by 
a pathologist and when the tumor cells were less than 70%, the FFPE section was macro-
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dissected. We searched for point mutations, deletions or insertions in EGFR exon 18 
(including codons 709 and 719), exon 19 (including codons from 746 to 753), exon 20 
(including codons 768, 770, 771, 776 and 790) and exon 21 (including codons 858 and 861) 
(Table 3.1). 
In addition we investigated KRAS point mutations in exon 2 (including codons 12 and 13), 
BRAF point mutations in exon 11 (including codons 466 and 469) and exon 15 (including 
codon 600) (Table 3.1). Furthermore, we analyzed HER2 genetic alterations paying attention 
to insertions in exon 20 (Table 3.1). The DS of PCR products was based on the Sanger 
method and was done using a 3130 Genetic Analyzer (Applied Biosystems). Finally, the 
electropherograms were analyzed with the appropriate software (SeqScape Software Version 
2.5
TM
, Applied Biosystems). Each sequence reaction was performed at least twice, starting 
from independent PCR reactions in order to confirm the DNA sequence. 
 
Gene 
Annealing 
temperature 
Primer Sequence 
PCR 
cycles 
EGFR 18 Fw 58
◦
C 5′-TCCAGCATGGTGAGGGCTGAG-3′ 40 
EGFR 18 Rv 58
◦
C 5′-GGCTCCCCACCAGACCATG-3′ 40 
EGFR 19 Fw 58
◦
C 5′-TGGGCAGCATGTGGCACCATC-3′ 40 
EGFR 19 Rv 58
◦
C 5′-AGGTGGGCCTGAGGTTCAG-3′ 40 
EGFR 20 Fw 58
◦
C 5′-CCTCCTTCTGGCCACCATGCG-3′ 40 
EGFR 20 Rv 58
◦
C 5′-CATGTGAGGATCCTGGCTCC-3′ 40 
EGFR 21 Fw 58
◦
C 5′-CCTCACAGCAGGGTCTTCTC-3′ 40 
EGFR 21 Rv 58
◦
C 5′-CCTGGTGTCAGGAAAATGCT-3′ 40 
KRAS 2 Fw 55◦C 5′-TGGTGGAGTATTTGATAGTGTA-3′ 45 
KRAS 2 Rv 55◦C 5′-CATGAAAATGGTCAGAGAA-3′ 45 
BRAF 11 Fw 52
◦
C 5′-TCCCTCTCAGGCATAAGGTAA-3′ 45 
BRAF 11 Rv 52
◦
C 5′-CGAACAGTGAATATTTCCTTTGAT-3′ 45 
BRAF 15 Fw 52
◦
C 5′-TCATAATGCTTGCTCTGATAGGA-3′ 45 
BRAF 15 Rv 52
◦
C 5′-GGCCAAAAATTTAATCAGTGGA-3′ 45 
HER2 20 Fw 57◦C 5′-CCATACCCTCTCAGCGTA-3′ 40 
HER2 20 Rv 57◦C 5′-GCTCCGGAGAGACCTGCAA-3′ 40 
 
Table 3.1: Primers used for PCR reactions. This table illustrates the annealing temperature, the 
primer sequence and the number of PCR cycles that were applied for the amplification of the different 
genes. Abbreviations: Fw, forward; Rv, reverse; PCR, polymerase chain reaction. 
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3.3) ALK and ROS1 gene status by FISH 
 
FISH was performed on 4-μm formalin-fixed, paraffin-embedded tissue sections treated using 
the Paraffin Pretreatment kit II (Pretreatment Reagent VP 2000, Abbott Molecular AG; Baar, 
Switzerland) according to the manufacturer’s instructions. The ALK FISH assay was done 
using the LSI ALK Dual Colour Break Apart Rearrangement Probe (Abbott Vysis; Illinois, 
North Chicago, USA) and the ROS1 FISH assay was performed with the SPEC ROS1 Dual 
Colour Break Apart Probe (Zytovision; Bremerhaven, Germania). The signals were evaluated 
with a fluorescent automated microscope (Zeiss
©
 Axioplan 2 Imaging, Oberkochen, 
Germany) equipped with a 100W UV lamp; an AxioCam camera (Zeiss
© 
AxioCam MRm) 
and single, double, triple band pass filters. In addition, the positive cases were analyzed also 
by the Bioview
©
 duet3 technology: an automatic platform for FISH fluorescent signal 
detection characterized by a fluorescent microscope, a software controlling filter, a software 
controlling focus and a digital camera. . 
ALK probe hybridizes in the 2p23 region and it is characterized by a dual colour (Spectrum 
Green and Spectrum Orange) break-apart methodology that permits to recognize ALK 
downstream and upstream sequences of the ALK usual breakpoints (Figure 3.1). The analyses 
are done counting cell by cell and observing the number of coloured fluorescent signals in the 
tissue. 
 
 
 
Figure 3.1: Schematic representation of the LSI ALK Dual Colour Break Apart Rearrangement 
Probe (Abbott Vysis). Abbreviations: ALK, Anaplastic Lymphoma receptor tyrosine Kinase. 
 
 
When the tumor cell is characterized by two fusion signals (i.e. two yellow signals) there is no 
ALK rearrangement. On the contrary, if the red signal is separated by the green one, the tumor 
cell carries the ALK rearrangement. In this case, if there is an intrachromosomal translocation 
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(e.g. EML4/ALK inversion) the signals are less than 2/3 diameters distant. On the contrary, if 
the distance is more than 3 diameters, there is an interchromosomal translocation. 
ROS1 probe hybridizes in the 6q22 region and it is a dual color break-apart probe like the 
aforementioned ALK probe. The green signal hybridizes next to the breakpoint cluster region 
(BCR) and the red one is distal (Figure 3.2). The interpretation of the signals is the same as 
that of ALK. 
 
 
 
Figure 3.2: Schematic representation of SPEC ROS1 Dual Colour Break Apart Probe 
(Zytovision). Abbreviations: Cen, Centromere; Tel, Telomere. 
 
 
For both ALK and ROS1 analyses, a minimum of 100 morphologically clear, non-
overlapping nuclei from at least 8-10 areas were scored for each tumor. In the case of small 
biopsies, the minimum considered for interpretation was 50 cells. Only experiments with at 
least 90% hybridization efficiency were considered. A tissue is considered positive for ALK or 
ROS1 rearrangements if this alteration is observed in at least 15% of cells (Yamaguchi T et al, 
2012). 
 
 
3.4) TTF-1 immunohistochemistry 
 
TTF-1 expression, the principal lung AC marker, was tested by immunohistochemistry (IHC). 
We used a mouse monoclonal antibody against TTF-1 (M3575
©
, Dako; Glostrup, Denmark). 
The presence of TTF-1 is demonstrated when some cells of the samples assume nuclear 
coloration. 
TTF-1 expression is reported on medical reports with values indicating the intensity, the 
distribution and the percentage of positive cells. 
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3.5) SensiScreen
®
 
 
EGFR genetic alterations were detected also by SensiScreen
®
, real-time PCR assays 
developed in a collaboration between our institute (Istituto Cantonale di Patologia, Locarno) 
and a Danish company (PentaBase ApS). 
 
3.5.1 SensiScreen
®
 validation on mutated cell lines  
SensiScreen
®
 assays development started with sensitivity studies on plasmids comprising 
sequences with different EGFR mutations (i.e. G719A, G719C, G719S, 746_750del, 
746_752del, 747_750del, 747_751del, 747_753del, 767_768ins, 769_770ins, 770_771ins, 
772_773ins, 773_774ins, 774_775ins, S768I, T790M, L858R, L861Q). Afterwards, 
sensitivity assays were conducted on DNA extracted from lung cell lines harbouring some 
EGFR mutations: NCI-H1650 (ATCC; Manassas, VA, USA; catalogue number: CRL-
5883
TM
) carrying E746_A750del in exon 19, HCC4006 (ATCC; catalogue number: CRL-
2871
TM
) carrying L747_A750del and A750P in exon 19, NCI-H1975 (ATCC; catalogue 
number: CRL-5908
TM
) carrying T790M in exon 20 and L858R in exon 21 (Table 3.2). The 
lung cell line HSAEC1-KT (ATCC; catalogue number: CRL-4050
TM
) was purchased in order 
to obtain wt DNA. The cell lines were subcultured in appropriate media according to the 
manufacturer’s instructions (ATCC) and genomic DNA was isolated using the QIAmp Mini 
kit (QIAGEN). Seven percentages of mutated cell line DNA in fixed amounts of wt DNA 
(10%, 1%, 0.5%, 0.1%, 0.05%, 0.01% and 0%) were tested by SensiScreen
®
 assay and DS. 
The analyses on cell lines and on plasmids permitted to define the sensitivity of these assays 
by the description of the limit of detection (LOD).  
After validation on DNA extracted from cell lines, the testing proceeded with the validation 
on DNA extracted from FFPE tissues of patients that has been previously characterized by 
DS. 
 
 
 
 
 
 
 
43 
 
Cell line EGFR mutation Origin 
NCI-H1650 (ATCC; 
CRL-5883
TM
) 
p.E746_A750delELREA (c.2235_2249del15) Lung AC 
HCC4006 (ATCC; 
 CRL-2871
TM
) 
p.L747_A750>P (c.2239_2248TTAAGAGAAG>C) 
+ p.A750P (c. 2248G>C) 
Lung AC 
NCI-H1975 (ATCC; 
CRL-5908
TM
) 
p.T790M (c.2369C>T) + p.L858R (c.2573T>G) Lung AC 
HSAEC1-KT (ATCC; 
CRL-4050
TM
) 
none (wt) Lung AC 
 
Table 3.2: Cell lines tested for SensiScreen
®
 validation.  Abbreviations: AC, adenocarcinoma. 
 
 
3.5.2 Mutational status of EGFR by SensiScreen
® 
SensiScreen
® 
contains Suprimer
TM
 (i.e. DNA primers modified with pentabases that will 
improve affinity, sensitivity, specificity and that will reduce primer-dimer formation); 
HydrolEasy
TM
 probes (fluorescent-labeled probes able to recognize a specific mutated 
sequence of the EGFR gene) and wt BaseBlockers
TM 
(WTB) (probes with a sequence that 
binds specifically to the wild-type DNA region, blocking the amplification of the wild-type 
DNA during PCR process) (Christensen UB and Pedersen EB, 2002; Christensen UB et al, 
2004). WTBs block the amplification of the wt sequence and allow the amplification of the 
mutant variant. 
In every SensiScreen
® 
assay, the reaction mixture is made of 300-900nM of each Suprimer
TM
, 
200nM of the probe, specific for each mutation, and 1000-5000nM of WTB. 
qPCR was performed using 50ng of  genomic DNA. The thermocycling conditions were: 
3΄(minutes, min) of initial activation of the hotstart taq-polymerase at 95°C, followed by 40 
cycles of a 2-step PCR with a 10΄΄ (seconds, s) denaturation step at 95°C and 30΄΄ extension 
step at 55°C (Riva A et al, 2017) (Figure 3.3).  
 
 
Figure 3.3: SensiScreen
® 
thermocycling conditions for EGFR characterization (Riva A et 
al, 2017). 
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Fluorescence was measured at the end of each extension step. The qPCR threshold cycle (Ct) 
of normalized fluorescence was used for the evaluation of the data. Ct is defined as the 
number of cycles where a fluorescence signal crosses the threshold. In order to make data 
analyses independent from the type of instrument used, the threshold was defined as 10% of 
the signal strength of the reference assay at cycle 45. For all valid samples (23< Ctreference<36), 
a ΔCt value was calculated by taking the Ct value of the mutation-specific assay and 
subtracting the Ct value of the reference assay: ΔCt = Ctmutation - Ctreference. 
Patient samples analysed by SensiScreen
® 
assays were classified as positive for a given 
mutation if the Ctmutation was ≤ 38 and the ΔCt was ≤9. 
SensiScreen
® 
assays have been developed for the analyses of three mutations in EGFR exon 
18 (i.e. G719A, G719C and G719S), for the most common deletions in EGFR exon 19 (e.g. 
746_750del, 746_752del, 747_751del and 747_753del), for the most diffuse insertions in 
EGFR exon 20 (e.g. 767_768ins, 769_770ins, 770_771ins, 772_773ins, 773_774ins, 
774_775ins), for two mutations in EGFR exon 20 (i.e. S768I and T790M) and for two 
mutations in EGFR exon 21 (i.e. L858R and L861Q). SensiScreen
® 
assays have been created 
in simplex version for G719A, G719C, G719S, S768I, T790M, L858R, L861Q mutations and 
in multiplex version for G719 mutations, exon 19 deletions or exon 20 insertions. Exon 20 
insertions multiplex is made of two reactions and G719 or exon 19 deletions multiplex by 
only one reaction.  
 
 
3.6) Plasma analyses 
 
Whole blood of patients affected by lung AC has been collected in Cell-Free DNA BCT
®
 
tubes (Streck; Omaha, Nebraska, USA), containing preservative reagents. These tubes are 
designed to minimize cfDNA degradation and to prevent the release of DNA from blood cells. 
After blood collection, the samples are reversed ten times and blood is stored at room 
temperature (RT) until plasma separation. 
 
3.6.1 Plasma separation 
Plasma separation is done within 48h after blood collection in Streck tubes. The mechanism is 
based on two centrifugation steps at 3000xg for 15΄ at RT. After centrifugation, the plasma 
component is transferred into a new, sterile tube and stored at -80°C until the DNA extraction 
and molecular characterization. 
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3.6.2 ctDNA analyses by cobas
® 
cfDNA extraction was done in 2mL of plasma obtained from patients affected by lung AC 
using cobas
®
 cfDNA sample preparation kit (Roche) according to the manufacturer’s 
instructions. After extraction, cfDNA was analyzed by cobas
®
 EGFR Mutation Test v2 (CE-
IVD) (Roche) following the standard protocol (available from: 
http://egfrmutationtestv2.roche.com/). The cobas
® 
EGFR Mutation Test v2 is a real-time PCR 
test that identifies 42 mutations in EGFR exons 18, 19,20 and 21 (e.g. L858R, L861Q, exon 
19 deletions and T790M). Amplification results are detected by cobas
®
 4800 system, software 
v2.1 or higher. The LODs for the EGFR mutations range from 2 to 13.4% (for details, see 
http://egfrmutationtestv2.roche.com/). 
 
3.6.3 ctDNA analyses by SensiScreen
® 
assays 
cfDNA was extracted from 500µL of plasma using QIAamp Mini kit (QIAGEN) according to 
the manufacturer’s instructions after an initial treatment at 57°C for 10΄ with 500µL of lysis 
buffer (AL) and 50µL of proteinase K (PK). 
The extracted cfDNA was tested by SensiScreen
® 
T790M liquid biopsy assay (PentaBase 
ApS) in order to identify the presence of the T790M mutation in the blood obtained from 
patients affected by lung AC. SensiScreen
®
 T790M liquid biopsy assay was developed by 
PentaBase ApS and our institute. This kit follows the same methodology aforementioned in 
paragraph 3.5 but it is characterized by a higher sensitivity compared to the SensiScreen
®
 
assay for T790M analyses on tissues. 
In addition, the analyses on cfDNA from plasma were done also for the other EGFR 
mutations for which we developed the SensiScreen
®
 assays in tissue (paragraph 3.5). 
Concerning these mutations, EGFR characterization of cfDNA was done using the same 
assays applied in tissues because they have enough sensitivity for the test on liquid biopsies. 
 
 
3.7) ROR1 expression analyses 
 
RNA extraction was done using the RNeasy FFPE kit (QIAGEN) according to the 
manufacturer’s instructions. In particular it was applied on two 10-µm FFPE tissue sections 
for each paired normal and tumor sample from the same patient.The tumor and normal area 
were selected by a pathologist. When the tumor cells in the cancerous tissue were less than 
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70%, the FFPE section was macro-dissected. 500 ng of RNA from each paired tumor and 
normal tissue was retro-transcribed in complementary DNA (cDNA) using the Superscript 
Vilo Master mix III (Invitrogen; Carlsbad, CA, USA). After RNA extraction and retro-
transcription in cDNA, ROR1 expression was evaluated by real-time PCR assays. To quantify 
the amplified cDNA, we used a TaqMan fluorescent probe (Applied Biosystems) recognizing 
the target gene (i.e. ROR1) and a TaqMan probe marked with a different fluorochrome 
recognizing a reference gene (i.e. the RN18S1 housekeeping gene, which encodes for the 18S 
rRNA). The reference gene is an internal control that must always be expressed at the same 
level in both normal and cancer tissues. TaqMan probes are characterized by a quencher (Q), 
a fluorochrome located on 3΄-end, and a reporter (R), a fluorochrome located on 5΄-end. 
During the real-time PCR amplification process, the probe recognizes the denaturated cDNA 
strand in ROR1 and DNA polymerase cleaves the probe, bringing to the split of Q and R. This 
division results in a fluorescent signal that is proportional to the number of DNA molecules 
obtained because the Q cannot mask R fluorescence when they are far away. 
For the amplification, we used 100ng and the test was repeated three times for each sample. 
The data were analyzed considering the threshold cycle in both cancer and normal tissues for 
each sample. We used the Livak method (Livak KJ and Schmittgen TD, 2001), that consists 
in the calculation of the 2
-ΔΔCt
 value. ΔΔCt is the difference between the sample ΔCt and the 
control ΔCt. Sample ΔCt is the difference between the Ct of the target gene (ROR1) and the 
Ct of the reference gene in tumor tissue. Control ΔCt is the difference between the Ct of the 
target gene (ROR1) and the Ct of the reference gene in normal tissue.  
 
ΔCt sample: Ct tumoral with ROR1 probe - Ct tumoral with RN18S1 probe 
ΔCt control: Ct normal with ROR1 probe - Ct normal with RN18S1 probe 
 
ΔΔCt: ΔCt sample - ΔCt control 
 
We fixed the value of 1 as cut-off, so in all the the samples with 2
-ΔΔCt
 value > 1 ROR1 has 
been considered overexpressed. 
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3.8) miR-382 expression analyses 
 
miRNAs extraction, retro-transcription and real-time were done by applying RecoverAll
TM 
Total Nucleic Acid Isolation Kit and TaqMan Advanced miRNA Assays (Applied 
Biosystems) according to the manufacturer’s instructions. For retro-transcription, we used 
10ng of RNA and a 1:10 dilution of the cDNA was used after retro-transcription, in order to 
use 5µL of the dilution in the real-time PCR experiment. The probes for real-time testing were 
two: hsa-miR-382-5p (Applied Biosystems) for miR-382 expression testing and hsa-miR-
451a (Applied Biosystems) for the evaluation of the housekeeping gene. For miR-382 
analyses, we applied again Livak method, as previously described (see 3.7), using the 
housekeeping gene miR-451a and comparing the threshold cycle for each sample in both 
cancer and normal tissues. A sample was considered as overexpressing miR-382 when 2
-ΔCt 
value was > 1. 
 
 
3.9) Statistical analyses 
 
The comparisons among genetic alterations in EGFR, KRAS, BRAF, HER2, ALK, ROS1 genes 
and the association of them with clinical-pathological characteristics were evaluated through 
the two-tailed Fisher’s exact test (available from: http://in-
silico.net/statistics/Fisher_exact_test). We set a value of statistical significance equal to 
p=0.05. 
This test has been applied also for the comparison between ROR1, miR-382 expression and 
for the association of them with clinical-pathological characteristics and the other molecular 
markers data. 
In addition, ROR1 and miR-382 were compared also by the determination of the Spearman 
correlation coefficient and of the Pearson correlation coefficient. These coefficients need to be 
near to 0 to demonstrate absence of correlation; in contrast, a value near to -1 or to 1 
demonstrate an opposite or concordant correlation, respectively. 
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4.1) Patients 
 
In our project we enrolled three cohorts of patients affected by lung AC.  
The first one was characterized for EGFR, KRAS, BRAF and HER2 by DS; for ALK and ROS1 
by FISH and for EGFR by SensiScreen
®
 assay (PentaBase ApS). The second cohort was 
analyzed by SensiScreen
®
 liquid biopsy kit for the analysis of the T790M mutation 
(PentaBase ApS) and by SensiScreen
®
 tissue kit for the other EGFR mutations (PentaBase 
ApS). In some samples we already had the molecular data obtained by IOT
®
, (Thermo Fisher 
Scientific) or TheraScreen
®
 (QIAGEN). In addition, we characterized 42 samples of this 
cohort also by cobas
®
 (Roche). The third cohort was characterized for EGFR, KRAS, BRAF 
and HER2 by DS, for ALK and ROS1 by FISH, and for ROR1 and miR-382 expression by 
real-time PCR. 
 
The first cohort is represented by 471 cases, 262 men (55.6%) and 209 women (44.4%), with 
a mean age at diagnosis of 68 years (range: 38-88 years). The primary tumor was analyzed in 
381 samples whereas in 90 cases the DNA was extracted from lung AC metastases 
characterized, in particular, by breast metastases (one patient), intestinal metastases (four 
patients), adrenal glands metastases (five patients), skin metastases (seven patients), liver 
metastases (ten patients), lymph nodes metastases (eighteen patients), brain metastases 
(twenty-four patients) and bone metastases (twenty-one patients).  
Histopathological T staging is available in 205 cases: 87 are classified as pT1, 81 as pT2, 26 
as pT3, 10 as pT4 and 1 as pTX (respectively 42.4%, 39.5%, 12.7%, 4.9% and 0.5% out of 
the available data). In addition, the N descriptor is available in 132 samples: 73 are classified 
as pN0, 23 as pN1, 30 as pN2 and 6 as pNX (respectively 55.3%, 17.4%, 22.7% and 4.6% out 
of the available data). M descriptor is equal to M1 in three patients (Table 4.1).  
Concerning tumor grading, the datum is available for 304 patients: 41 are classified as G1, 91 
as G2, 157 as G3, 5 as G1/G2, 8 as G2/G3 and 2 as G4 (respectively 13.6%, 29.9%, 51.6%, 
1.6%, 2.6% and 0.7% out of the available data) (Table 4.1).   
 
The second cohort is characterized by 61 plasma, 5 serum and 39 tissue samples. In 9 cases, 
blood was collected before the treatment with EGFR TKIs (up-front patients) and in 52 cases 
after their administration. All the serum samples were obtained from patients after treatment 
with TKIs. Concerning tissues, 23 patients are up-front and 16 cases were previously treated 
with TKIs. 
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In 22 patients we succeeded to collect both plasma and tissue associated samples:  
- 16 associated tissue pre-treatment and plasma post-treatment samples 
- 1 associated tissue post-treatment and plasma post-treatment samples 
- 5 associated tissue post- plus pre-treatment and plasma post-treatment samples 
In 5 patients we analyzed paired plasma and serum samples.  
The 39 tissue samples are from patients with a mean age at diagnosis of 63 years (range: 35-
84 years). In this group, there are 18 men and 21 women (46.2% and 53.8% out of the tissue 
samples) (Table 4.2). 
The 66 liquid biopsies samples are from patients with a mean age at diagnosis of 66 years 
(range: 39-87 years). In particular, the patients from which we obtained liquid biopsies are 
subdivided in  32 men and 34 women (48.5% and 51.5% out of this group) (Table 4.3).  
In this cohort we do not have information concerning the histopathological staging and the 
grade of differentiation. 
 
The third cohort is represented by 102 cases, 48 men (47.1%) and 54 women (52.9%), with a 
mean age at diagnosis of 64 years (range: 40-86 years). For all the patients of this group we 
analyzed the primary tumor and, if possible, we selected also the normal tissue in order to do 
the comparisons necessary for the the analysis of ROR1 and miR-382 by real-time 
experiments. 
The histopathological T descriptor is available in 71 patients: 31 are defined as T1, 22 as T2, 
18 as T3 (respectively 43.6%, 31%, and 25.4% out of the available data). N staging is 
described in 58 cases: 29 are N0, 8 are N1, 20 are N2 and 1 is N3 (respectively 50%, 13.8%, 
34.5% and 1.7% out of the available data). Only one patient is M1 (Table 4.4). 
The differentiation grade of the tumor is available in 89 samples: 15 are classified as G1, 3 as 
G1/G2, 32 as G2, 5 as G2/G3, 33 as G3 and 1 as G4 (respectively 16.8%, 3.4%; 36%, 5.6%; 
37.1% and 1.1% out of the available data) (Table 4.4). 
This cohort has been selected for ROR1 study because we have clinical data concerning the 
treatment, the PFS and the OS. In particular 32 patients (31.4%) underwent surgery, 17 
(16.7%) surgery followed by chemotherapy, 16 (15.7%) surgery followed by chemotherapy 
and radiotherapy, 22 (21.6%) chemotherapy with palliative purpose, 2 (1.9%) radiotherapy 
with palliative purpose, 11 (10.8%) chemotherapy followed by radiotherapy (specifically six 
with palliative purpose; five with curative intent) and 2 (1.9%) received TKIs vs EGFR 
(specifically afatinib).  
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In patients treated with chemotherapy the PFS is equal to 9 months whereas OS is equal to 11 
months in case of palliatiave intent and 40 months in case of curative intent. 
These data are not available for targeted therapies because only two patients received TKIs. 
 
Cohort 1 
Patients characteristics (n=471) Number of cases Pecentage (%) 
Age 
≥ mean (68) 229 48.6 
< mean (68) 242 51.4 
Gender 
male 262 55.6 
female 209 44.4 
Staging: T 
descriptor (n=205) 
T0 0 - 
TX 1 0.5 
T1 87 42.4 
T2 81 39.5 
T3 26 12.7 
T4 10 4.9 
Staging: N 
descriptor (n=132) 
N0 73 55.3 
NX 6 4.6 
N1 23 17.4 
N2 30 22.7 
N3 0 - 
N4 0 - 
Differentiation 
(n=304) 
GX 0 - 
G1 41 13.6 
G1/G2 5 1.6 
G2 91 29.9 
G2/G3 8 2.6 
G3 157 51.6 
G4 2 0.7 
 
Table 4.1: Cohort 1. Clinical-pathological characteristics. Abbreviations: n, number. 
 
 
Cohort 2 
Tissue samples 
Patients characteristics (n=39) Number of cases Pecentage (%) 
Age 
≥ mean (63) 15 38.5 
< mean (63) 24 61.5 
Gender 
male 18 46.2 
female 21 53.8 
 
Table 4.2: Cohort 2, tissue samples. Clinical-pathological characteristics. Abbreviations: n, number. 
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Cohort 2 
Liquid biopsies (plasma and serum) samples 
Patients characteristics (n=66) Number of cases Pecentage (%) 
Age 
≥ mean (66) 31 47.0 
< mean (66) 35 53.0 
Gender 
male 32 48.5 
female 34 51.5 
 
Table 4.3: Cohort 2, liquid biopsies. Clinical-pathological characteristics. Abbreviations: n, number. 
 
 
Cohort 3 
Patients characteristics (n=102) Number of cases Pecentage (%) 
Age 
≥ mean (64) 46 45.1 
< mean (64) 56 54.9 
Gender 
male 48 47.1 
female 54 52.9 
Staging T 
descriptor (n=71) 
T0 0 - 
TX 0 - 
T1 31 43.6 
T2 22 31 
T3 18 25.4 
T4 0 - 
Staging N 
descriptor (n=58) 
N0 29 50 
NX 0 - 
N1 8 13.8 
N2 20 34.5 
N3 1 1.7 
N4 0 - 
Differentiation  
(n=89) 
GX 0 - 
G1 15 16.8 
G1/G2 3 3.4 
G2 32 36 
G2/G3 5 5.6 
G3 33 37.1 
G4 1 1.1 
Treatment  
(n=102) 
surgery 32 31.4 
surgery+chemotherapy 17 16.7 
surgery+chemotherapy+radiotherapy 16 15.7 
palliative chemotherapy 22 21.6 
palliative radiotherapy 2 1.9 
chemotherapy+radiotherapy 11 10.8 
afatinib  2 1.9 
 
Table 4.4: Cohort 3. Clinical-pathological characteristics. Abbreviations: n, number. 
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4.2) Cohort one  
 
4.2.1 Molecular markers characterization by DS  
In the first cohort (n= 471) we observed mutations in 185 patients (Figure 4.1), corresponding 
to 39.2% of the cases. In particular: 67/468 EGFR mutated cases, 110/471 KRAS exon 2 
mutated cases, 8/457 BRAF mutated cases and 2/462 HER2 exon 20 mutated cases, 
representing 14.3%, 23.3%, 1.7% and 0.4% out of the evaluable samples respectively. In 
EGFR, we identified four mutations in exon 18, twenty-eight in exon 19, fifteen in exon 20 
and twenty-four in exon 21. In the totality of the EGFR mutations, equal to 71, the different 
exons (18, 19, 20 and 21) were mutated in 5.6%, 39.4%, 21.2% and 33.8% of the cases, 
respectively. In BRAF, we detected four mutations in both exon 11 and exon 15 respectively. 
The specific mutations are shown in Table 4.5. In this cohort we found that twelve patients 
harboured two mutations: one sample is mutated in EGFR and KRAS (i.e. patient 112 in Table 
4.5 is E746_A750 del in EGFR exon 19 and G12V in KRAS exon 2); one sample is mutated in 
EGFR and BRAF (i.e. patient 173 in Table 4.5 is T847I in EGFR exon 21 and G469A in 
BRAF exon 11); eight samples are mutated in two different EGFR exons (e.g. patient 189 in 
Table 4.5 is E746_A750del in exon 19 and T790M in exon 20) and two samples have a 
double mutation in the same EGFR exon (i.e. patients 155 and 321 in Table 4.5 have double 
mutations in EGFR exon 19 and exon 21 respectively) (Table 4.5).  
 
n 
Cohort 1: samples mutated by Sanger 
sequencing  
 
n 
Cohort 1: samples mutated by Sanger 
sequencing 
EGFR 
(ex) 
KRAS 
ex 2 
BRAF 
(ex) 
HER2 
ex 20 
 EGFR 
(ex) 
KRAS 
ex 2 
BRAF 
(ex) 
HER2 
ex 20 
1 wt G12V wt wt  182 L861Q (21) wt wt wt 
2 wt G12C wt wt 
 
189 
E746_A750 
del (19)  
+ T790M (20) 
wt wt wt 
3 wt G12C wt wt 
 
190 
E746_A750 
del (19)  
+ T790M (20) 
wt wt wt 
5 wt G13C wt wt  191 wt wt V600E 
(15) 
wt 
6 wt G12C wt wt  193 L747_A750 
del (19) 
wt wt wt 
7 L858R (21) wt wt wt  194 E746_S752 
del (19) 
wt wt wt 
10 wt G12A wt wt  195 wt wt wt E770_A771 
ins AYVM 
11 wt G12C wt wt  196 S752_I759  
del (19) 
wt wt wt 
13 wt G12C wt wt  197 G719S (18) 
+ S768I (20) 
wt wt wt 
14 wt G13D wt wt  198 G719S (18) 
+ S768I (20) 
wt wt wt 
16 wt G12C wt wt  199 G719S (18) 
+ S768I (20) 
wt wt wt 
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n 
Cohort 1: samples mutated by Sanger 
sequencing  
 
n 
Cohort 1: samples mutated by Sanger 
sequencing 
EGFR 
(ex) 
KRAS 
ex 2 
BRAF 
(ex) 
HER2 
ex 20 
 EGFR 
(ex) 
KRAS 
ex 2 
BRAF 
(ex) 
HER2 
ex 20 
17 wt wt wt 
A775_G776 
ins YVMA 
 202 H773_V774 
ins NPH (20) 
wt wt wt 
18 wt G12C wt wt  203 L747_T751 
del (19) 
wt wt wt 
20 wt G12D wt wt  204 L747_T751  
del (19) 
wt wt wt 
22 wt G13R wt wt  205 T790M (20) 
+ L858R (21) 
wt wt wt 
28 
L747_S753  
del (19) 
wt wt wt  206 E746_A750 
del (19) 
wt wt wt 
29 L858R (21) wt wt wt  208 wt G12A wt wt 
30 wt G12C wt wt  209 E746_A750 
del (19) 
wt wt wt 
32 wt G12D wt wt  215 D770_N771 
ins SVE (20) 
wt wt wt 
36 
G719A (18) 
+ S768I (20) 
wt wt wt  222 wt wt T440A 
(11) 
wt 
37 wt wt V600E 
(15) 
wt  223 wt G12C wt wt 
40 wt G12D wt wt  226 wt G12C wt wt 
46 wt wt V600E 
(15) 
wt  228 wt G12V wt wt 
47 wt G12R wt NE  230 wt G12C wt wt 
48 wt G12V wt wt  231 wt G12D wt wt 
49 wt G12C wt wt  232 wt G12D wt wt 
50 wt G12C wt wt  233 E746_A750 
del (19) 
wt wt wt 
54 L858R (21) wt wt wt  236 wt G12C wt wt 
56 L747P (19) wt wt wt  240 wt G13C wt wt 
59 
E746_A750 
del (19) 
wt wt wt  241 E746_A750 
del (19) 
wt wt wt 
63 wt G12C wt wt  246 E746_A750 
del (19) 
wt wt wt 
66 NE G12C NE NE  247 L858R (21)  wt wt 
70 T790M (20) wt wt wt  253 wt G12D wt wt 
80 
E746_A750 
del (19) 
wt NE NE  255 wt G12V wt wt 
81 
P772_H773 
ins PR (20) 
wt NE NE  256 L858R (21)  wt wt 
82 wt G12V NE NE  258 wt G12C wt wt 
83 wt G12C wt wt  259 wt G12C wt wt 
84 wt wt G469V 
(11) 
wt  268 wt G12C wt wt 
88 
E746_A750 
del (19) 
wt wt wt  273 E709G (18) 
+ L858R (21) 
wt wt wt 
89 T790M (20) wt wt wt  275 wt G12D wt wt 
96 wt G12C wt wt  279 wt G12V wt wt 
99 wt G12A wt wt  280 wt G12C wt wt 
101 T790M (20) wt wt wt  283 wt G12C wt wt 
104 wt G12V wt wt  284 wt G12C wt wt 
108 
H773_V774 
ins NPH (20) 
wt wt wt  285 wt G12A wt wt 
109 
D770_N771 
ins G (20) 
wt wt wt  294 wt G12V wt wt 
112 
E746_A750 
del (19) 
G12V wt wt  295 wt G12C wt wt 
118 
E746_A750 
del (19) 
wt wt wt  296 wt G12V wt wt 
119 wt wt V600E 
(15) 
wt  301 wt G12C wt wt 
120 wt G12C wt wt  308 wt G12D wt wt 
121 wt G12C wt wt  309 wt G12C wt wt 
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n 
Cohort 1: samples mutated by Sanger 
sequencing  
 
n 
Cohort 1: samples mutated by Sanger 
sequencing 
EGFR 
(ex) 
KRAS 
ex 2 
BRAF 
(ex) 
HER2 
ex 20 
 EGFR 
(ex) 
KRAS 
ex 2 
BRAF 
(ex) 
HER2 
ex 20 
122 wt wt G469V 
(11) 
wt  313 wt G12C wt wt 
126 wt G12C wt wt  316 wt G12D wt wt 
127 wt G12A wt wt  317 wt G12V wt wt 
128 wt G12C wt wt  318 wt G12V wt wt 
129 wt G12C wt wt  319 wt G12C wt wt 
130 wt G12C wt wt  320 wt G12V wt wt 
132 wt G12C wt wt  321 L858M  
+ L861Q (21) 
wt wt wt 
133 wt G12C wt wt  324 L861Q (21) wt wt wt 
134 wt G12C wt wt  325 wt G12C wt wt 
136 wt G12V wt wt  329 wt G12C wt wt 
138 wt G12C wt wt  332 wt G12C wt wt 
139 wt G12V NE NE  333 wt G12C wt wt 
140 wt G12A wt wt  336 wt G12C wt wt 
141 wt G12C wt wt  338 wt G12A wt wt 
142 wt G12A wt wt  340 wt G12C wt wt 
144 wt G12D wt wt  345 E746_A750 
del (19) 
wt wt wt 
145 
E746_A750 
del (19) 
wt wt wt  348 L858R (21) wt wt wt 
147 wt G12C NE wt  352 L858R (21) wt wt wt 
148 wt G12V wt wt  353 wt G12V wt wt 
149 wt G12V wt wt  356 L858R (21) wt wt wt 
150 
E746_S752 
del (19) 
wt wt wt  359 wt G12D wt wt 
153 wt G12V wt wt  361 L858R (21) wt wt wt 
154 T790M (20) wt wt wt  366 wt G12V wt wt 
155 
E746G  
+ L747S (19) 
wt wt wt  368 wt G12V wt wt 
156 
E746_A750 
del (19) 
wt wt wt  371 wt G12A wt wt 
159 wt G12C wt wt  375 wt G12D wt wt 
163 wt G12C wt wt  376 L858R (21) wt wt wt 
164 S752F (19) wt wt wt  377 wt G12C wt wt 
165 
E746_A750 
del (19) 
wt NE NE  378 wt G12C wt wt 
166 wt G12A wt wt  379 wt G12D wt wt 
168 wt G12C wt wt  381 wt G12C wt wt 
169 wt G12V wt wt  383 wt G12D wt wt 
170 wt G12C wt wt  384 wt G12D wt wt 
171 wt G12C wt wt  385 wt G12D wt wt 
172 wt G12V wt wt  406 L858R (21) wt wt wt 
173 
T847I 
(21) 
wt G469A 
(11) 
wt  429 L858R (21) wt wt wt 
174 
E746_S752 
del (19) 
wt wt wt  440 L858R (21) wt wt wt 
175 wt G12R wt wt  445 E746_A750 
del (19) 
wt wt wt 
176 L858R (21) wt wt wt  450 L861Q (21) wt wt wt 
177 
K745_E746 
ins IPVAIK 
(20) 
wt wt wt 
 
451 L858R (21) wt wt wt 
           
           
           
           
56 
 
 
n 
Cohort 1: samples mutated by Sanger 
sequencing  
 
n 
Cohort 1: samples mutated by Sanger 
sequencing 
EGFR 
(ex) 
KRAS 
ex 2 
BRAF 
(ex) 
HER2 
ex 20 
 EGFR 
(ex) 
KRAS 
ex 2 
BRAF 
(ex) 
HER2 
ex 20 
178 
E746_S752 
del (19) 
wt wt NE  455 L858R (21) wt wt wt 
181 L861Q (21) wt wt wt       
 
Table 4.5: Cohort 1-samples mutated in EGFR (exons 18, 19, 20 and 21), KRAS (exon 2), BRAF 
(exons 11 and 15) and HER2 (exon 20) by Sanger sequencing. This table shows only the patients 
with mutations. Abbreviations: ex, exon; n, sample number; NE, not evaluable; wt, wild-type. In 
brackets it is reported the exon that is mutated. 
 
 
 
 
Figure 4.1: Examples of electropherograms obtained by DS. These pictures represent four different 
EGFR mutations corresponding to overlapping peaks: A) The change from GAA codon (position 709) 
to GAG codon brings to E709G mutation in EGFR exon18. B) Sequence of EGFR exon 19 in codon 
747 containing a deletion from 747 codon to 752 codon (L747_S752del). C) The change from ACG 
codon (position 790) to ATG codon brings to T790M mutation in EGFR exon20. D) The change from 
CTG (position 858) codon to CGG codon brings to L858R mutation in exon 21.  
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4.2.2 ALK and ROS1 FISH results 
FISH was conducted only in samples for which we had enough material available after the 
other analyses. In cohort one, we analysed ALK in 262 patients and ROS1 in 261 patients. 
Fourteen cases were not evaluable for ALK and sixteen for ROS1. Nine cases are rearranged 
in ALK and one in ROS1, representing 3.6% (9/248) and 0.4% (1/245) out of the evaluable 
samples, respectively (Table 4.6, Figure 4.2 and 4.3).  
n 
Cohort 1: 
FISH 
 
n 
Cohort 1: 
FISH 
 
n 
Cohort 1: 
FISH 
 
n 
Cohort 1:  
FISH  
ALK ROS1  ALK ROS1  ALK ROS1  ALK ROS1 
1 - neg  222 neg neg  300 neg neg  377 neg neg 
2 - neg  223 neg neg  301 neg neg  378 neg neg 
3 - neg  224 neg neg  302 neg neg  379 neg neg 
4 - neg  225 neg neg  304 neg NE  380 neg neg 
6 - neg  226 neg neg  305 neg neg  381 neg NE 
7 - neg  227 neg neg  306 neg neg  382 neg NE 
8 - neg  228 neg neg  307 neg NE  383 neg neg 
10 neg NE  229 neg neg  308 neg neg  384 pos neg 
11 - neg  230 neg NE  309 neg neg  385 neg neg 
13 - neg  231 NE neg  310 neg neg  386 neg neg 
14 - neg  232 neg neg  311 neg neg  387 neg neg 
15 - neg  233 neg neg  312 neg neg  388 neg neg 
16 - neg  234 neg neg  313 neg neg  389 neg - 
18 - neg  235 neg neg  314 neg neg  390 neg neg 
20 - neg  237 neg neg  315 neg neg  391 pos neg 
21 - neg  238 neg neg  316 neg neg  392 neg neg 
22 - neg  239 neg neg  317 neg neg  393 - neg 
23 - neg  240 neg neg  318 neg neg  394 - neg 
24 - neg  241 neg neg  319 neg neg  395 - neg 
25 - neg  242 neg neg  320 neg neg  396 - neg 
26 - neg  243 neg neg  321 neg neg  398 neg - 
28 - neg  244 neg neg  322 neg neg  403 neg neg 
29 - neg  245 neg neg  323 neg neg  405 pos - 
30 - neg  246 neg neg  324 neg neg  406 neg - 
32 - neg  247 neg neg  325 neg neg  407 neg neg 
33 - neg  248 neg neg  326 neg neg  408 neg - 
34 - neg  249 neg neg  327 neg neg  409 neg - 
35 - neg  250 neg neg  328 neg neg  410 neg - 
36 pos neg  251 neg neg  329 neg neg  411 neg neg 
37 - neg  252 neg neg  330 neg neg  412 neg neg 
38 - neg  253 neg neg  331 neg neg  413 pos - 
39 - neg  254 neg neg  332 neg neg  414 neg neg 
40 neg neg  255 neg neg  333 neg neg  416 neg neg 
41 - neg  256 neg neg  334 pos neg  417 pos neg 
42 - neg  257 NE neg  335 neg neg  418 neg - 
56 neg neg  258 neg neg  336 neg neg  419 neg - 
88 neg -  259 neg neg  337 neg neg  420 neg neg 
127 neg -  260 neg neg  338 neg neg  423 neg neg 
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Table 4.6: Cohort 1-ALK and ROS1 FISH results. Abbreviations: n, sample number; NE; not 
evaluable; neg; sample negative for ALK or ROS1 rearrangement; pos, sample positive for ALK or 
ROS1 rearrangement. 
 
 
n 
Cohort 1: 
FISH 
 
n 
Cohort 1: 
FISH 
 
n 
Cohort 1: 
FISH 
 
n 
Cohort 1: 
FISH 
ALK ROS1  ALK ROS1  ALK ROS1  ALK ROS1 
154 neg -  261 NE neg  339 neg neg  424 neg neg 
162 neg pos  262 NE neg  340 neg neg  425 neg neg 
166 neg neg  263 neg neg  341 neg neg  426 neg neg 
167 - neg  264 neg neg  342 neg neg  427 neg neg 
168 - neg  265 neg neg  343 neg neg  429 neg neg 
169 - neg  266 neg neg  344 neg neg  431 pos - 
170 - neg  267 neg neg  345 neg neg  432 neg - 
171 - neg  268 neg neg  346 neg neg  433 neg - 
172 - neg  269 neg neg  347 neg neg  434 neg neg 
173 neg neg  270 neg neg  348 neg neg  436 neg neg 
175 neg -  271 neg neg  349 neg neg  437 neg neg 
176 neg -  272 neg neg  350 neg neg  439 neg - 
177 neg -  273 neg neg  351 neg neg  440 neg - 
179 neg -  274 neg neg  352 neg neg  441 neg neg 
180 neg -  275 neg neg  353 neg neg  442 neg - 
181 neg neg  276 neg neg  354 neg neg  443 neg neg 
185 neg neg  277 neg neg  355 neg neg  444 neg neg 
186 neg neg  278 neg neg  356 neg neg  445 neg - 
188 neg neg  279 NE neg  357 neg neg  446 neg - 
192 neg neg  280 neg neg  358 neg neg  449 neg neg 
193 neg -  281 NE neg  359 neg neg  452 neg - 
194 neg -  283 neg neg  360 neg neg  454 neg - 
195 neg neg  284 neg neg  361 neg neg  455 neg - 
199 neg neg  285 neg neg  362 neg neg  456 neg  
207 neg neg  286 neg neg  363 neg neg  457 neg - 
208 neg neg  287 neg neg  364 neg neg  458 neg - 
209 neg neg  288 NE neg  365 neg neg  459 neg - 
210 neg neg  289 neg neg  366 neg neg  461 neg - 
211 neg neg  290 neg neg  367 neg neg  462 neg neg 
212 neg neg  291 neg neg  368 neg neg  463 neg neg 
213 neg neg  292 neg neg  369 neg neg  464 neg - 
214 neg neg  293 neg neg  370 neg neg  465 neg - 
215 neg neg  294 neg neg  371 neg neg  466 neg - 
217 NE neg  295 neg neg  372 neg neg  467 neg neg 
218 NE neg  296 neg neg  373 neg neg  468 neg neg 
219 neg neg  297 neg neg  374 neg neg  469 pos neg 
220 neg neg  298 neg neg  375 neg neg  470 neg - 
221 neg neg  299 neg neg  376 neg neg  471 neg - 
59 
 
 
 
Figure 4.2: FISH analyses for identification of rearrangements in ALK gene. A) FISH picture 
obtained by Bioview
©
 duet3 technology. It represents an ALK positive sample: indeed in addition to 
the normal yellow signals there are also distant red and green fluorescences. B) FISH picture obtained 
by automated fluorescent microscope (Zeiss
© 
Axioplan 2 Imaging). It represents an ALK negative 
sample: in fact, there are only yellow signals or near red and green fluorescences. 
 
 
 
 
Figure 4.3: FISH analyses for identification of rearrangements in ROS1 gene. A) FISH picture 
obtained by automated fluorescent microscope. It represents a ROS1 positive sample: indeed in 
addition to the normal yellow signals there are also distant red and green fluorescences. B) FISH 
picture obtained by automated fluorescent microscope. It represents a ROS1 negative sample: in fact, 
there are only yellow signals or near red and green fluorescences. Figures are obtained from 
ZytoVision
 
brochure. 
 
 
4.2.3 TTF-1 IHC results 
 
In cohort one the cases with enough residual tissue material were screened for TTF-1 
expression by IHC. Consequently we tested 321 samples: 252/321 (78.5%) patients are 
positive for TTF-1 antibody staining and 69/321 (21.5%) are negative (Table 4.7 and Figure 
4.4).  
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Cohort 1  Cohort 1  Cohort 1  Cohort 1  Cohort 1  Cohort 1 
n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
1 neg  80 neg  206 pos  278 pos  349 pos  417 pos 
2 neg  87 pos  208 neg  279 pos  350 pos  418 pos 
3 pos  89 pos  211 pos  281 neg  351 pos  419 pos 
4 pos  90 pos  212 pos  282 neg  353 pos  420 pos 
5 pos  92 pos  213 pos  283 neg  355 pos  421 neg 
6 neg  95 pos  214 pos  284 pos  356 pos  422 neg 
7 pos  97 pos  215 pos  285 pos  357 pos  423 neg 
8 neg  100 pos  216 pos  286 pos  359 pos  424 neg 
9 pos  102 pos  217 pos  289 pos  360 neg  425 neg 
10 pos  105 pos  218 pos  291 pos  361 pos  426 pos 
11 pos  109 pos  219 pos  292 neg  363 neg  427 pos 
12 pos  113 pos  220 neg  294 pos  364 pos  428 neg 
13 pos  114 pos  222 neg  297 pos  365 pos  429 pos 
14 pos  115 pos  223 pos  298 pos  366 pos  430 pos 
15 pos  122 neg  224 pos  299 pos  368 neg  431 pos 
16 pos  123 pos  225 pos  300 neg  369 neg  432 pos 
17 pos  124 pos  226 neg  301 neg  370 pos  433 neg 
18 pos  126 pos  227 neg  302 pos  371 pos  434 pos 
19 pos  130 neg  228 pos  303 pos  372 pos  435 pos 
20 pos  135 pos  231 pos  304 pos  373 pos  436 pos 
21 pos  137 pos  232 neg  306 pos  378 pos  437 pos 
22 neg  140 neg  235 pos  307 pos  379 neg  438 pos 
23 pos  146 pos  236 neg  309 pos  380 neg  439 pos 
24 neg  147 pos  237 neg  310 pos  382 pos  440 pos 
25 pos  148 pos  238 pos  312 pos  385 pos  441 pos 
26 pos  149 pos  240 pos  313 neg  387 pos  442 pos 
27 pos  152 pos  241 pos  315 neg  388 pos  443 pos 
28 pos  154 pos  243 pos  316 pos  391 pos  444 pos 
29 pos  155 pos  246 pos  317 pos  392 pos  445 pos 
30 pos  157 pos  250 pos  318 neg  393 pos  446 pos 
31 pos  159 neg  251 pos  319 pos  394 pos  447 pos 
32 pos  163 pos  252 pos  320 neg  395 pos  448 neg 
33 pos  165 pos  253 neg  321 pos  396 pos  449 pos 
34 pos  166 pos  254 pos  323 neg  397 pos  450 pos 
35 pos  167 pos  255 neg  325 pos  398 pos  451 pos 
36 pos  168 neg  256 pos  327 neg  399 pos  452 neg 
37 pos  169 neg  257 pos  328 neg  400 pos  453 neg 
38 pos  170 neg  258 neg  329 neg  401 pos  454 neg 
39 pos  171 pos  259 pos  330 neg  402 pos  455 neg 
40 pos  172 pos  260 pos  332 pos  403 pos  456 neg 
41 pos  173 pos  261 neg  333 neg  404 neg  457 pos 
42 pos  174 pos  262 pos  334 pos  405 pos  458 pos 
43 pos  175 neg  263 neg  337 pos  406 pos  459 neg 
55 pos  177 pos  264 neg  338 pos  407 pos  460 pos 
57 pos  178 pos  265 pos  339 pos  408 pos  461 pos 
63 pos  181 pos  266 pos  340 pos  409 pos  462 pos 
65 pos  183 pos  267 pos  341 pos  410 pos  463 pos 
66 pos  184 pos  268 pos  342 pos  411 pos  464 neg 
67 pos  187 pos  269 neg  343 pos  412 pos  465 pos 
68 pos  192 pos  270 pos  344 pos  413 pos  466 pos 
69 pos  194 pos  271 neg  345 pos  414 pos  467 pos 
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Cohort 1  Cohort 1  Cohort 1  Cohort 1  Cohort 1  Cohort 1 
n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
72 pos  195 pos  272 pos  346 pos  415 pos  468 pos 
74 pos  196 pos  275 pos  348 pos  416 pos  469 pos 
75 pos  199 pos  276 pos          
 
Table 4.7: Cohort 1-TTF-1 IHC results. Abbreviations: n, sample number; neg; sample negative for 
TTF-1 expression; pos, sample positive for TTF-1 expression. 
 
 
 
 
Figure 4.4: Positive TTF-1 IHC staining. Lung AC sample presenting expression of TTF-1 in the 
cellular nucleus (enlargement: 20X) (Figure obtained from The Human Protein Atlas). 
 
 
4.2.4 EGFR characterization by SensiScreen
®
 
In order to validate SensiScreen
®
 assays, we searched for EGFR mutated cell lines in 
published articles. During the development of SensiScreen
®
, we repeated several times the 
sensitivity assays with mutated plasmids and DNA extracted from mutated cell lines, in order 
to obtain an assay with high sensitivity. After some changes in reagents concentrations and in 
other main reaction parameters, we succeded in the development of a kit with a LOD between 
0.1%, and 1%, corresponding to the detection of until 1 copy of mutant DNA in a wt 
background. The development of the reagents contained in EGFR SensiScreen
®
 lung was 
based on the results obtained with KRAS SensiScreen
®
 kit in colorectal cancer. The latter kit 
is CE IVD and the data obtained for colorectal cancer has already been published by our 
laboratory, in collaboration with PentaBase ApS (Riva A et al, 2017). 
In addition, DS confirmed that DNA extracted from the subcultured lung AC cell lines is 
really mutated, as found in literature (cell lines mutations are reported in Table 3.2). 
After the development of the kits, we proceeded with the validation of EGFR SensiScreen
®
 
assays on DNA extracted from lung tumoral tissue samples. To do this, we tested 
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SensiScreen
®
 kit in cohort one and we compared the results with the data obtained by DS. In 
the first cohort, all the EGFR multiplex and simplex assays (i.e. G719A, G719C and G719S 
in exon 18; exon 19 deletions; exon 20 insertions; S768I and T790M in exon 20; L858R and 
L861Q in exon 21) confirmed the mutations found by DS (Table 4.8 and Figure 4.5).  
More importantly, SensiScreen
®
 assays were able to detect additional mutated cases 
compared to DS: exon 19 deletions multiplex revealed four new mutated samples (patients 
number 175, 179, 239 and 287), exon 20 insertions multiplex two new mutated samples 
(patients number 202 and 315), T790M simplex two new mutated samples (patients number 
156 and 256), L858R simplex five new mutated samples (patients number 28, 44, 113, 128 
and 310) and L861Q simplex one new mutated sample (patient number 248) (Table 4.8). No 
additional mutated cases were found by G719 simplex and multiplex and S768I simplex 
SensiScreen
®
 assays. Samples number 57, 66 and 213, defined as not evaluable by DS, 
resulted wt with all the developed SensiScreen
®
 kit. 
Table 4.8 reports the percentages of the new mutated samples detected by SensiScreen
®
,
 
compared to DS. 
 
Cohort 1: new mutated samples (DS vs SensiScreen
®
) 
EGFR assay 
Mutated cases identified by 
Additional mutated cases 
identified by SensiScreen
®
 
DS SensiScreen
®
 n % 
G719 simpl and mplx 
(exon 18) 
4/468 4/471 0 - 
exon 19 deletions 
mplx 
21/468 25/471 4 19% 
exon 20 insertions 
mplx 
5/468 7/471 2 40% 
T790M simpl 
(exon 20) 
6/468 8/471 2 33% 
S768I simpl 
(exon 20) 
4/468 4/471 0 - 
L858R simpl 
(exon 21) 
11/468 16/471 5 45% 
L861Q simpl 
(exon 21) 
3/468 4/471 1 33% 
 
Table 4.8: Cohort 1-Comparison between DS and SensiScreen
® 
assays. This table reports the 
number of EGFR mutated cases detected by DS or SensiScreen
®
 and the percentages of the new 
mutated cases with respect to the number of mutated cases by DS. SensiScreen
®
 found 14 additional 
mutant cases compared to DS. Abbreviations: DS, direct sequencing; mplx, multiplex; n, sample 
number; simpl, simplex. 
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Figure 4.5: Plot resulting from EGFR SensiScreen
®
 assays in a mutated patient. The blue 
curve represents the signal of the mutation (in this case, the T790M mutation) and the pink curve 
represents the signal of the reference gene. Abbreviations: RFU, relative fluorescence units. 
 
 
4.3) Cohort two  
 
4.3.1 Plasma analyses 
The patients in cohort two (characterized by plasma samples and, in some cases, by the 
associated tissue or serum sample) were tested by SensiScreen
® 
assays for EGFR mutations 
(i.e. G719A, G719C and G719S in exon 18; exon 19 deletions; exon 20 insertions; S768I in 
exon 20; L858R and L861Q in exon 21) validated, as aforementioned, in lung tissues and by a 
SensiScreen
®
 T790M assay especially developed for liquid biopsies. T790M liquid biopsies 
test has been adapted from tissue assays in order to be more sensible and to be able to detect 
the highly fragmented and low concentrated DNA contained in plasma samples. This kit has 
been modified changing the concentration of reagents that are contained in the assays 
developed for tissue characterization.  
In this cohort, the patients were previously characterized by SensiScreen® assays and other 
methodologies in order to compare the EGFR results obtained with different methodologies.  
From analyses conducted before our characterization experiments, we have: DS results in 
samples from 1 to 4 (Table 4.9); IOT
®
 Oncomine cell-free nucleic acids assay data (Thermo 
Fisher Scientific) in samples 20, 21, 22 and in samples from 86 to 105 (Table 4.9) and 
TheraScreen
®
 (QIAGEN) characterization in samples from 23 to 85 (Table 4.9). 
In addition, in the samples for which we had enough material, or that were not previously 
characterized by other methodologies different than SensiScreen
®
 (patients from 5 to 22 and 
patients from 35 to 58), we applied cobas
® (Roche) (Table 4.9). 
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4.3.2 DS, IOT
®
, TheraScreen
®
 and cobas
®
 results 
The results obtained by the other methodologies, necessary for comparisons with 
SensiScreen
® 
assays, are reported in table 4.9.  
 
Cohort 2: DS, IOT
®
, TheraScreen
®
 and  
cobas
®
 EGFR (ex) results 
 Cohort 2: DS, IOT
®
, TheraScreen
®
 and 
cobas
®
 EGFR (ex) results 
n  DS IOT® Thera® cobas®  n  DS IOT® Thera® cobas® 
1 t 
E746_A750 
del (19) 
- - -  54 p - - wt wt 
2 p wt - - -  55 p - - wt wt 
3 t 
E746_A750 
del (19) 
- - -  56 p - - wt wt 
4 p wt - - -  57 p - - wt wt 
5 p - - - del (19)  58 p - - wt wt 
6 p - - - wt 
 
59 t - - 
del (19)  
+ T790M 
(20) 
- 
7 p - - - wt 
 
60 t - - 
del (19)  
+ T790M 
(20) 
- 
8 p - - - wt  61 t - - wt - 
9 p - - - del (19)  62 t - - wt - 
10 p - - - wt  63 t - - wt - 
11 p - - - wt  64 t - - wt - 
12 p - - - wt  65 t - - del (19) - 
13 p - - - wt  66 t - - del (19) - 
14 p - - - wt  67 t - - del (19) - 
15 p - - - wt  68 t - - del (19) - 
16 p - - - wt  69 t - - del (19) - 
17 p - - - 
del (19)  
+ T790M 
(20) 
 
70 t - - del (19) - 
18 p - - - wt  71 t - - del (19) - 
19 p - - - wt  72 t - - del (19) - 
20 p - wt - wt  73 t - - del (19) - 
21 p - 
E746_A750 
del (19)  
+ L858R 
(21) 
- 
del (19)  
+ L858R 
(21) 
 
74 t - - del (19) - 
22 p - 
T790M 
(20)  
+ L858R 
(21) 
- 
T790M 
(20)  
+ L858R 
(21) 
 
75 t - - del (19) - 
23 p - - wt -  76 t - - NE - 
24 p - - wt -  77 t - - 
L858R 
(21) 
- 
25 p - - wt -  78 t - - 
L858R 
(21) 
- 
26 s - - wt - 
 
79 t - - 
L858R  
(21 ) 
+ S768I 
(20) 
- 
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Cohort 2: DS, IOT
®
, TheraScreen
®
 and  
cobas
®
 EGFR (ex) results 
 Cohort 2: DS, IOT
®
, TheraScreen
®
 and  
cobas
®
 EGFR (ex) results 
n  DS IOT® Thera® cobas®  n  DS IOT® Thera® cobas® 
27 p - - 
L858R 
(21) 
- 
 
80 t - - 
L858R 
(21)  
+ S768I 
(20) 
- 
28 s - - 
L858R 
(21) - 
 81 t - - 
L861Q 
(21) 
- 
29 p - - 
L858R 
(21) - 
 82 t - - NE - 
30 s - - 
L858R 
(21) - 
 83 t - - NE - 
31 p - - 
T790M 
(20)  
+ L858R 
(21) 
- 
 
84 t - - NE - 
32 s - - 
T790M 
(20)  
+ L858R 
(21) 
- 
 
85 t - - wt - 
33 p - - wt -  86 t - wt - - 
34 p - - wt - 
 
87 t - 
T790M 
(20) + 
L858R (21) 
- - 
35 p - - 
T790M 
(20) 
T790M 
(20) 
 
88 t - 
T790M 
(20) + 
L858R (21) 
- - 
36 p - - 
T790M 
(20) 
T790M 
(20) 
 89 t - 
E746_A750 
del (19) 
- - 
37 p - - 
T790M 
(20) 
T790M 
(20) 
 90 t - 
E746_A750 
del (19) 
- - 
38 p - - 
T790M 
(20) 
T790M 
(20) 
 
91 t - 
T790M 
(20) + 
L858R (21) 
- - 
39 p - - 
T790M 
(20) 
T790M 
(20) 
 92 t - wt - - 
40 p - - 
T790M 
(20)  
+ L858R 
(21) 
T790M 
(20)  
+ L858R 
(21) 
 
93 t - 
E746_A750
del (19) 
- - 
41 p - - 
T790M 
(20) 
T790M 
(20) 
 
94 t - 
E746_A750 
del (19) + 
T790M 
(20) 
- - 
42 p - - 
T790M 
(20) 
T790M 
(20) 
 95 t - wt - - 
43 p - - wt wt 
 
96 p - 
T790M 
(20) + 
L858R (21) 
- - 
44 p - - wt wt 
 
97 p - 
T790M 
(20) + 
L858R (21) 
- - 
45 p - - wt wt 
 
98 p - 
T790M 
(20) + 
L858R (21) 
- - 
46 p - - NE NE  99 p - wt - - 
47 p - - wt wt  100 p - wt - - 
48 p - - wt wt 
 
101 p - 
T790M 
(20) + 
L858R (21) 
- - 
49 p - - wt wt 
 
102 p - 
T790M 
(20) + 
L858R (21) 
- - 
50 p - - wt wt 
 
103 p - 
T790M 
(20) + 
L858R (21) 
- - 
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Cohort 2: DS, IOT
®
, TheraScreen
®
 and  
cobas
®
 EGFR (ex) results 
 Cohort 2: DS, IOT
®
, TheraScreen
®
 and  
cobas
®
 EGFR (ex) results 
n  DS IOT® Thera® cobas®  n  DS IOT® Thera® cobas® 
51 p - - wt wt 
 
104 p - 
T790M 
(20) + 
L858R (21) 
- - 
52 p - - wt wt 
 
105 p - 
T790M 
(20) + 
L858R (21) 
- - 
53 p - - wt wt        
  
Table 4.9: Cohort 2-EGFR results obtained by DS, IOT
®
, TheraScreen
®
 or cobas
® 
on plasma 
and some tissue associated samples. By TheraScreen
®
 and by cobas
®
 is not possible to define the 
specific deletion. Abbreviations: DS, direct sequencing; ex, exon; IOT
®
, Ion Torrent; n, sample 
number; NE, not evaluable; p, plasma; s, serum; t, tissue; thera, TheraScreen
®
; wt, wild-type. 
 
 
4.3.3 SensiScreen
®
 results  
In the second cohort, all the EGFR multiplex and simplex tissue kit (i.e. G719A, G719C and 
G719S in exon 18; exon 19 deletions; exon 20 insertions; S768I in exon 20; L858R and 
L861Q in exon 21) and the T790M (exon 20) liquid biopsy simplex kit confirmed the 
mutations found by the other methodologies described in paragraph 4.3.2 (Table 4.9).  
In addition, SensiScreen
®
 assays were able to detect additional mutated cases compared to 
TheraScreen
® 
and
 
cobas
®
: L858R (exon 21) simplex kit revealed two new mutated sample 
(patient number 48, 49) (Table 4.10 and 4.11). The five samples (four tissues and one plasma) 
that were not evaluable by the other methodologies resulted evaluable and wt in SensiScreen
®
 
analyses. 
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Cohort 2 plasma and serum samples: new mutated cases  
EGFR assay 
Mutated cases identified by 
Additional mutated cases 
identified by SensiScreen
®
 
Other 
methodology 
SensiScreen
®
 n % 
G719 simpl and mplx 
(exon 18) 
0/65 0/66 0 - 
exon 19 deletions 
mplx 
4/65 4/66 0 - 
exon 20 insertions 
mplx 
0/65 0/66 0 - 
T790M simpl 
(exon 20) 
17/65 17/66 0 - 
S768I simpl 
(exon 20) 
0/65 0/66 0 - 
L858R simpl 
(exon 21) 
14/65 16/66 2 14% 
L861Q simpl 
(exon 21) 
0/65 0/66 0 - 
 
Table 4.10: Cohort 2-Comparison between the other methodologies and SensiScreen
®
 EGFR 
assays in plasma and serum samples. This table reports the number of mutated cases detected by 
other methodologies or SensiScreen
®
 and the percentages of the new mutated cases with respect to the 
total of the mutations found by another technology. SensiScreen
®
 found 2 additional mutant cases 
compared to TheraScreen
®
. Abbreviations: mplx, multiplex; n, sample number; simpl, simplex. 
 
 
Cohort 2 tissue samples: new mutated cases  
EGFR assay 
Mutated cases identified by 
Additional mutated cases 
identified by SensiScreen
®
 
Other 
methodology 
SensiScreen
®
 n % 
G719 simpl and mplx 
(exon 18) 
0/35 0/39 0 - 
exon 19 deletions 
mplx 
19/35 19/39 0 - 
exon 20 insertions 
mplx 
0/35 0/39 0 - 
T790M simpl 
(exon 20) 
6/35 6/39 0 - 
S768I simpl 
(exon 20) 
2/35 2/39 0 - 
L858R simpl 
(exon 21) 
7/35 7/39 0 - 
L861Q simpl 
(exon 21) 
1/35 1/39 0 - 
 
Table 4.11: Cohort 2-Comparison between the other methodologies and SensiScreen
®
 EGFR 
assays in tissue samples. This table reports the number of mutated cases detected by other 
methodologies or SensiScreen
®
 and the percentages of the new mutated cases. SensiScreen
®
 did not 
find new additional mutant cases compared to other methodologies but confirms all the results. 
Abbreviations: mplx, multiplex; n, sample number; simpl, simplex. 
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4.4) Cohort three 
 
4.4.1 Molecular markers characterization by DS  
In the third cohort (n=102) we observed 54 mutated patients (Figure 4.1), corresponding to 
52.9% of the cases. EGFR alterations were detected in 13/101 patients; KRAS mutations in 
41/100 patients; BRAF mutations in 3/79 patients and HER2 alterations in 1/81 patients, 
representing 12.9%, 41%, 3.8% and 1.2% out of the evaluable cases, respectively. One patient 
is mutated in EGFR exon 18, six in exon 19, two in exon 20 and five in exon 21. In the 
totality of the EGFR mutations, equal to fourteen, the different exons are altered in 7.1%, 
42.9%, 14.3% and 35.7% of the cases, respectively. Two patients are mutated in BRAF exon 
11 and one in exon 15. The specific mutations are reported in Table 4.12.  
In this cohort we found that five patients harboured two mutations: two sample are mutated in 
EGFR and KRAS (i.e. patient 32 in Table 4.12 is D800N in EGFR exon 20 and G12C in 
KRAS exon 2; patient 50 in Table 4.12 is Y827F in EGFR exon 21 and G12C in KRAS exon 
2); one sample is mutated in KRAS and BRAF (i.e. patient 23 in Table 4.12 is G12C in KRAS 
exon 2 and D594G in BRAF exon 15); one sample is mutated in EGFR and BRAF (i.e. patient 
94 in Table 4.12 is T847I in EGFR exon 21 and G469A in BRAF exon 11) and one sample is 
mutated in two different EGFR exons (i.e. patient 59 in Table 4.12 is E746_A750del in exon 
19 and T790M in exon 20) (Table 4.12). 
 
n 
Cohort 3: samples mutated by 
Sanger sequencing  
 
n 
Cohort 3: samples mutated by 
Sanger sequencing 
EGFR 
(ex) 
KRAS 
ex 2 
BRAF 
(ex) 
HER2 
ex 20 
 
EGFR 
(ex) 
KRAS 
ex 2 
BRAF 
(ex) 
HER2 
ex 20 
6 wt G12V wt wt  55 L747_T751 
del (19) wt NE NE 
7 wt G12C wt wt  57 wt G12C wt wt 
8 
E746_A750 
del (19) 
wt NE NE  58 wt G12D wt wt 
10 wt G12C wt wt 
 
59 
E746_A750 
del (19)  
+ T790M 
(20) 
wt wt wt 
12 wt G12V wt wt  61 wt G12C wt wt 
14 wt G12V wt wt  63 wt G12V wt wt 
15 
E746_A750 
del (19) 
wt NE NE  64 wt G12A wt wt 
17 wt G12D wt wt  65 wt G12D wt wt 
19 wt wt wt 
A775_G
776 ins 
YVMA 
 
71 
L747_S752 
del (19) wt wt wt 
23 wt G12C D594G 
(15) 
wt  73 L858R (21) wt wt wt 
24 wt G12C wt wt  75 wt G12C wt NE 
28 
E746_A750 
del (19) 
wt wt wt  76 wt G12C wt wt 
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n 
Cohort 3: samples mutated by 
Sanger sequencing  
 
n 
Cohort 3: samples mutated by 
Sanger sequencing 
EGFR 
(ex) 
KRAS 
ex 2 
BRAF 
(ex) 
HER2 
ex 20 
 
EGFR 
(ex) 
KRAS 
ex 2 
BRAF 
(ex) 
HER2 
ex 20 
32 D800N (20) G12C NE wt  78 wt G12D wt wt 
33 wt G13R wt wt  79 wt G12C wt wt 
35 wt G12C wt wt  80 wt G13D NE NE 
36 wt G12C NE NE  81 wt G12C wt wt 
37 wt G12D wt wt  85 wt G13C wt wt 
39 wt G13D wt wt  86 wt G12V wt wt 
44 wt G12C wt wt  90 G719A (18) wt wt wt 
46 wt G12A wt wt  91 wt G12C wt NE 
48 wt G12C wt wt  92 wt G12C wt wt 
49 wt G12V NE wt  93 wt wt V600E 
(15) wt 
50 Y827F (21) G12C NE NE  94 T847I (21) wt G469A 
(11) 
wt 
51 L858R (21) wt wt wt  95 wt G12C wt wt 
52 wt G12V wt wt  96 L858R (21) NE NE NE 
53 wt G13C wt wt  97 wt G12V wt wt 
54 wt G12C NE wt  99 wt G12D wt wt 
 
Table 4.12: Cohort 3-samples mutated in EGFR (exons 18, 19, 20 and 21), KRAS (exon 2), BRAF 
(exons 11 and 15) and HER2 (exon 20) by Sanger sequencing. This table shows only the patients 
with mutations. Abbreviations: ex, exon; n, sample number; NE, not evaluable; wt, wild-type. In 
brackets it is reported the exon that is mutated. 
 
 
4.4.2 ALK and ROS1 FISH results 
In cohort three, ALK analyses were done in 31 cases and ROS1 analyses in 78 cases. Seven 
cases were not evaluable for ALK and twenty for ROS1. In this cohort, we found one ALK 
translocation (4.2% out of the evaluable patients) but we did not detect any ROS1 alterations 
(Table 4.13 and Figure 4.2).  
 
n 
Cohort 3: 
FISH 
 
n 
Cohort 3: 
FISH 
 
n 
Cohort 3: 
FISH 
 
n 
Cohort 3: 
FISH 
ALK ROS1  ALK ROS1  ALK ROS1  ALK ROS1 
1 neg -  39 - neg  66 neg neg  84 neg neg 
3 - neg  42 neg -  67 neg neg  85 neg neg 
7 - neg  44 - neg  68 - neg  86 neg neg 
9 - neg  46 neg NE  69 - neg  87 - neg 
10 - neg  47 neg neg  70 - neg  88 - neg 
11 neg NE  48 - neg  72 neg neg  89 neg neg 
12 - neg  50 - neg  73 - neg  90 pos neg 
13 - neg  51 - neg  74 neg neg  92 - neg 
14 neg -  52 - neg  75 neg neg  93 - neg 
17 - neg  54 - neg  76 - neg  94 neg neg 
22 - neg  57 - neg  78 - neg  95 - neg 
24 - neg  59 - neg  79 neg NE  97 - neg 
30 neg NE  61 - neg  80 neg neg  98 - neg 
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n 
Cohort 3: 
FISH 
 
n 
Cohort 3: 
FISH 
 
n 
Cohort 3: 
FISH 
 
n 
Cohort 3: 
FISH 
ALK ROS1  ALK ROS1  ALK ROS1  ALK ROS1 
31 - neg  62 - neg  81 - neg  99 neg neg 
32 - neg  63 - neg  82 neg neg  100 - neg 
33 - neg  64 neg neg  83 - neg  102 neg neg 
35 - neg             
 
Table 4.13: Cohort 3-ALK and ROS1 FISH results. Abbreviations: n, sample number; NE; not 
evaluable; neg; sample negative for ALK or ROS1 rearrangement; pos, sample positive for ALK or 
ROS1 rearrangement 
 
 
4.4.3 TTF-1 IHC results 
In the cases of cohort three with enough residual tissue material we screened for TTF-1 
expression by IHC. Therefore we tested 74 samples. In cohort three, 55/74 (74.3%) are 
positive for TTF-1 expression, whereas 19/74 cases (25.7%) showed a negative staining to the 
antibody (Table 4.14 and Figure 4.4).  
 
Cohort 3  Cohort 3  Cohort 3  Cohort 3  Cohort 3  Cohort 3 
n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
 n 
TTF-1 
IHC 
2 pos  27 pos  48 neg  61 neg  75 pos  89 pos 
3 pos  29 pos  49 neg  62 neg  76 pos  90 pos 
7 pos  31 pos  50 neg  63 pos  77 pos  91 pos 
9 pos  32 pos  51 neg  64 pos  78 pos  92 pos 
10 pos  33 neg  52 neg  65 pos  81 neg  93 pos 
11 pos  35 pos  53 pos  68 neg  82 pos  94 pos 
12 neg  39 pos  54 neg  69 pos  83 pos  95 pos 
13 pos  40 pos  55 neg  70 pos  84 neg  97 pos 
17 pos  41 pos  56 neg  71 pos  85 neg  98 pos 
19 pos  43 pos  57 pos  72 pos  86 pos  99 pos 
22 neg  44 pos  59 pos  73 pos  87 pos  100 pos 
24 neg  46 pos  60 pos  74 pos  88 pos  101 pos 
26 neg  47 pos             
 
Table 4.14: Cohort 3-TTF-1 IHC results. Abbreviations: n, sample number; neg; sample negative 
for TTF-1 expression; pos, sample positive for TTF-1 expression. 
 
 
4.4.4 ROR1 expression 
In the third cohort, we evaluated ROR1 expression, by TaqMan real-time PCR (Applied 
Biosystems), in 58/102 samples for which we had sufficient tissue material left for the 
extraction of RNA. Indeed, in some cases, there was not enough tissue for these analyses after 
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the extraction of the DNA used for DS (paragraph 4.4.1). In addition, in some patients we had 
not the availability of normal tissue that is necessary for the evaluation of the data.  
Two samples (2/58, 1.3% out of the tested samples) resulted not evaluable because the 
extracted RNA was highly degraded.  
The comparison between ROR1 and the housekeeping gene (reference) RN18S in both 
tumoral and normal tissues was done by applying of the Livak method through the calculation 
of the 2
-ΔΔCt
 value.  
In 16 samples (28.6% out of the evaluable cases) ROR1 resulted overexpressed in tumour 
compared to normal tissue, presenting a 2
-ΔΔCt
 value > 1. On the contrary, in 40 patients 
(71.4% out of the evaluable cases) the expression of ROR1 was not significantly different 
between tumour and normal tissue, indeed 2
-ΔΔCt
 values resulted ≤ 1 (Table 4.15). 
 
Cohort 3: ROR1 results  Cohort 3: ROR1 results  Cohort 3: ROR1 results 
n 2
-ΔΔCt
 
ROR1 
expression 
 n 2-ΔΔCt 
ROR1 
expression 
 n 2-ΔΔCt 
ROR1 
expression 
2 1.10 +  48 0.72 -  78 0.70 - 
3 0.69 -  51 1.09 +  80 NE NE 
7 0.25 -  52 0.67 -  81 0.16 - 
10 1.51 +  53 0.16 -  82 1.01 + 
12 0.20 -  54 0.10 -  83 0.08 - 
13 0.72 -  57 1.03 +  85 NE NE 
17 0.16 -  59 0.50 -  86 1.20 + 
19 0.69 -  61 0.23 -  87 0.34 - 
22 1.64 +  62 0.46 -  88 0.35 - 
24 3.66 +  63 0.99 -  89 0.38 - 
27 2.50 +  64 0.09 -  90 1.58 + 
29 0.57 -  68 0.45 -  92 1.21 + 
31 0.16 -  69 0.11 -  93 0.29 - 
35 0.10 -  70 0.21 -  95 0.35 - 
39 0.15 -  71 0.35 -  97 1.41 + 
40 0.44 -  73 0.71 -  98 1.97 + 
43 1.67 +  75 0.71 -  99 0.21 - 
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Cohort 3: ROR1 results  Cohort 3: ROR1 results  Cohort 3: ROR1 results 
n 2
-ΔΔCt
 
ROR1 
expression 
 n 2-ΔΔCt 
ROR1 
expression 
 n 2-ΔΔCt 
ROR1 
expression 
44 0.72 -  76 0.12 -  100 1.54 + 
46 0.55 -  77 1.85 +  101 0.51 - 
47 0.75 -         
 
Table 4.15: Cohort 3 - ROR1 expression obtained by TaqMan real-time. The comparison between 
ROR1 and RN18S (housekeeping gene) in tumour and normal tissue was done applying the Livak 
method. Abbreviations: Ct, threshold cycle; n, sample number; NE, not evaluable; ROR1, receptor 
tyrosine kinase-like orphan receptors. 
 
 
4.4.5 miR-382 expression 
 
In the third cohort, miR-382 expression was evaluated, by TaqMan real-time PCR (Applied 
Biosystems) in 54/102 samples for which we had sufficient tissue material left for the 
extraction of RNA. Indeed, in some cases there was not enough tissue for these analyses after 
the extraction of the DNA used for DS (paragraph 4.4.1) and after the extraction of the RNA 
used for ROR1 real-time (paragraph 4.4.4). In addition, in some patients we had not the 
availability of the normal tissue that is necessary for the evaluation of the data. In this cohort 
two samples (2/54, 3.7% out of the tested samples) resulted not evaluable because the 
extracted RNA was highly degraded.  
Applying the calculation of 2
-ΔCt
 value we were able to compare miR-382 expression in 
tumoral and normal tissues. In 25 samples (48.1% out of the evaluable cases) miR-382 
resulted overrepresented in tumour compared to normal tissue, presenting a 2
-ΔCt
 value > 1. 
On the contrary, in 27 patients (51.9% out of the evaluable cases) the expression of miR-382 
was not significantly different between tumour and normal tissue, indeed 2
-ΔCt 
values resulted 
≤ 1 (Table 4.16). 
For miR-382 evaluation we considered 2
-ΔCt
 and not 2
-ΔΔCt
 (obtained comparing the results of 
the miRNA probe and the housekeeping probe) because the values of the triplicates with the 
probe of the reference gene were different and could not be considered as reliable or 
replicable. 
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Cohort 3: miR-382 results  Cohort 3: miR-382 results  Cohort 3: miR-382 results 
n 2
-ΔCt
 
miR-382  
expression 
 n 2-ΔCt 
miR-382  
expression 
 n 2-ΔCt 
miR-382  
expression 
2 0.10 -  53 0.09 -  80 1.78 + 
3 2.20 +  57 1.83 +  81 1.63 + 
7 7.11 +  59 0.20 -  82 0.59 - 
10 3.07 +  61 2.51 +  83 1.12 + 
12 0.93 -  62 0.04 -  85 0.21 - 
13 1.80 +  63 0.11 -  86 0.26 - 
17 0.07 -  64 5.19 +  87 0.02 - 
22 5.24 +  68 0.03 -  88 4.28 + 
24 0.53 -  69 0.07 -  89 1.61 + 
29 2.41 +  70 6.15 +  90 0.02 - 
31 2.59 +  71 NE NE  92 0.06 - 
35 1.85 +  72 0.72 -  93 6.96 + 
39 1.37 +  73 0.06 -  95 5.37 + 
44 0.05 -  74 1.78 +  97 0.84 - 
46 0.28 -  75 1.53 +  98 0.97 - 
48 0.10 -  76 0.09 -  99 1.45 + 
51 0.48 -  77 1.83 +  100 0.14 - 
52 1.37 +  78 0.20 -  101 NE NE 
 
Table 4.16: Cohort 3 - miR-382 expression obtained by TaqMan real-time. The evaluation of 
miR-382 expression was made by calculation of the 2
-ΔCt
 value between tumour tissue and normal 
tissues. Abbreviations: Ct, threshold cycle; n, sample number; NE, not evaluable. 
 
 
4.5) Statistical analyses 
The data obtained from the analyses of our three cohorts can be compared and can be better 
understood by applying different statistical analyses. 
 
4.5.1 Correlations between molecular alterations and clinical-pathological 
data and between the molecular status of the different genes 
In the three cohorts, the two-tailed Fisher’s exact statistical test between the clinical-
pathological characteristics of the patients (sex, age, TNM classification, differentiation 
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grade) and the molecular data (EGFR, KRAS, BRAF, HER2 mutations; ALK and ROS1 
rearrangements; TTF-1 IHC expression) revealed no correlations.  
However the two-tailed Fisher’s exact test revealed a statistical, significant correlation 
between EGFR and KRAS in cohorts one and three (Table 4.17). In particular the alterations 
in EGFR and KRAS were nearly mutually exclusive. In addition BRAF and KRAS wt cases 
tend to be TTF-1 positive. A correlation was considered positive when the p value, calculated 
with Fisher’s test, was minor than 0.05. 
 
Two-tailed Fisher’s exact test 
Cohort 1 Cohort 3 
p=0.005 
EGFR 
p=0.02 
EGFR 
mut wt mut wt 
K
R
A
S
 
mut 1 109 
K
R
A
S
 
mut 1 40 
wt 66 292 wt 11 48 
 
 
Two-tailed Fisher’s exact 
test 
Cohort 1 
p=0.0007 
KRAS 
mut wt 
T
T
F
-1
 
pos 47 183 
neg 26 35 
 
 
Two-tailed Fisher’s exact 
test 
Cohort 1 
p=0.02 
BRAF 
mut wt 
T
T
F
-1
 
pos 2 124 
neg 2 57 
 
Table 4.17: Cohort 1 or  3- Correlations demonstrating statistical significance applying the two-
tailed Fisher’s exact test analyses. A p value minor than 0.05 indicates a correlation between the two 
compared molecular marker. Abbreviations: EGFR, Epidermal Growth Factor Receptor; KRAS, 
Kirsten Rat sarcoma viral oncogene homolog; mut, mutated; neg, negative; p, p value; pos, positive; 
TTF-1, Thyroid Transcription Factor-1 ; wt, wild-type.   
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4.5.2 Correlation of ROR1 with clinical-pathological data and molecular 
data of the other molecular markers 
In the third cohort, the two-tailed Fisher’s exact test was applied to compare ROR1 to 
clinical-pathological data  (sex, age, TNM classification, differentiation grade, treatment, PFS 
and OS) and no significant correlations were observed. 
Furthermore, the comparison between the alterations occurring in the other molecular markers 
(EGFR, KRAS, BRAF, HER2 mutations; ALK and ROS1 rearrangements; TTF-1 IHC 
expression) and ROR1 expression did not show any significant correlation as well, again 
using the two-tailed Fisher’s exact test (Table 4.18). 
 
Two-tailed Fisher’s exact 
test 
p=1 ROR1 
mut wt 
K
R
A
S
 
mut 9 16 
wt 11 20 
 
 
Two-tailed Fisher’s exact 
test 
p=1 ROR1 
mut wt 
E
G
F
R
 
mut 2 3 
wt 18 33 
 
 
Two-tailed Fisher’s exact 
test 
p=1 ROR1 
mut wt 
B
R
A
F
 
mut 0 1 
wt 20 35 
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Two-tailed Fisher’s exact 
test 
p=1 
ROR1 
mut wt 
H
E
R
2
 
mut 0 1 
wt 19 35 
 
 
Two-tailed Fisher’s exact 
test 
p=1 ROR1 
mut wt 
A
L
K
 mut 1 0 
wt 2 6 
 
 
Two-tailed Fisher’s exact 
test 
p=1 ROR1 
mut wt 
R
O
S
1
 mut 0 0 
wt 17 28 
 
 
Two-tailed Fisher’s exact 
test 
p=1 ROR1 
mut wt 
T
T
F
-1
 
pos 16 29 
neg 4 7 
 
Table 4.18: Cohort 3 - Correlation between ROR1 expression and the other molecular markers. 
In all the cases the p value is major than 0.05 consequently there is no correlation between ROR1 and 
the alterations or expression of the other genes. Abbreviations: ALK, Anaplastic Lymphoma 
receptor tyrosine Kinase; EGFR, Epidermal Growth Factor Receptor; KRAS, Kirsten Rat sarcoma 
viral oncogene homolog; mut, mutated; neg, negative; p, p value; pos, positive; ROR1, receptor 
tyrosine kinase-like orphan receptors; TTF-1, Thyroid Transcription Factor-1; wt, wild-type. 
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4.5.3 Association between ROR1 and miR-382 
The association between ROR1 and its associated miR-382 was calculated through the 
Spearman correlation coefficient and the Pearson correlation coefficient. These two values 
were respectively equal to 0.05 and -0.04, indicating that in our cohort there is neither 
opposite nor concordant correlation between ROR1 and miR-382 expression because these 
results are different from 1 and -1 and are close to 0. Also by applying the two-tailed Fisher’s 
exact test there is no correlation between their expression, indeed the p value resulted > 0.05 
(i.e. 0.76) (Table 4.19). 
 
Two-tailed Fisher’s 
exact test 
p=0.76 ROR1 
> 1 ≤ 1 
m
iR
-3
8
2
 
> 1 7 15 
≤ 1 10 15 
 
Table 4.19: Cohort 3 - Correlation between ROR1 and miR-382 expression. The p value obtained 
by the two-tailed Fisher’s exact test is major than 0.05 consequently there is no correlation between 
ROR1 and miR-382. We considered values ≤ 1 as negative expression and > 1 as positive expression. 
Abbreviations: p, p value; ROR1, receptor tyrosine kinase-like orphan receptors. 
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5. DISCUSSION 
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Nowadays the care of patients affected by lung cancer represents one of the biggest 
challenges in medicine because this tumor is characterized by the highest mortality rate (equal 
to 27% of all cancer deaths) and by an incidence that is second only to sex related tumors 
(Travis WD et al, 2004; Siegel R et al, 2015; Cancer.org. Cancer facts and figures 2016. 
American Cancer Society; Travis WD et al, 2016). These statistical data highlight the 
relevance of the development of new treatments, especially in AC, the most common 
histotype among lung cancers (Corrin B, 2000; Herbst RS et al, 2008). To date, in patients 
with advanced lung AC, tumor resection is combined with platinum (cis-Pt or carbo-Pt)-
doublet based chemotherapy, but these drugs are limited by their lack of specificity for tumor 
tissues and by frequent and potentially severe dose-limiting toxicities.  
To solve these limitations, in recent times, there has been the development of molecular 
targeted therapies (Kaneda H et al, 2013). In lung AC, the approved targeted therapies are 
small-molecule, tyrosine kinase inhibitors (TKIs) acting against EGFR, ALK and ROS1 
alterations; furthermore, last years have also seen the evaluation, in several clinical trials, of 
therapies against other mutations (e.g. alterations in HER2, BRAF and KRAS genes) (Tsao AS 
et al, 2016).  
Despite all the successful trials based on targeted therapies, a huge number of cases cannot 
benefit from the administration of these specific drugs. Indeed, about 50% of lung AC patients 
display a normal gene sequence for the genes that are currently used or under investigation as 
predictive markers of response to targeted therapies; in particular only up to 20% of patients 
carry EGFR mutations and, as a consequence, may benefit from 1st-2nd generation TKIs. After 
treatment with EGFR inhibitors, a specific mechanism of acquired resistance occurs in 50-
60% of cases: the creation of the T790M mutation. However, Pharma companies have 
developed new, specific drugs against this alteration, such as osimertinib (Tagrisso®; 
AZD9291; Astra Zeneca).  
The low rate of lung AC patients that can be treated by the currently approved TKIs is also 
related to the fact that, sometimes, mutations in the aforementioned genes are missed because 
of the poor quantity and quality characterizing the majority of lung AC tissue specimens. 
Indeed, with the current methodologies (e.g. direct sequencing, DS), is really difficult to 
estimate the molecular profile of the low concentrated material because the sensitivity of this 
assay is insufficient. Furthermore, the mutations can be skipped due to the fact that lung ACs 
are an extremely heterogeneous type of tumor, and therefore only a small fraction of cells 
could show a specific mutation.  
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The need to find a solution to all these limitations created the basis for my PhD project. In 
particular, the aim of my research activities was to improve the care of patients affected by 
lung AC following two strategies: firstly, we tried to enhance the characterization of 
molecular markers for targeted therapies and, secondly, we characterized the expression of a 
new putative marker for targeted therapies, ROR1. In this way we hope to enlarge the group 
of patients that can avoid standard chemotherapies by addressing them to specific targeted 
therapies. 
 
We improved the characterization of molecular markers for EGFR-targeted therapies through 
the development and the validation, in collaboration with a Danish company (PentaBase), of a 
new real-time PCR based assay (EGFR SensiScreen
®
). This methodology was created in two 
versions (for DNA obtained from tissue samples and for DNA obtained from liquid biopsies) 
and the new assays were compared to other methodologies (DS, IOT, TheraScreen
®
 and 
cobas
®
) in terms of sensitivity and specificity.  
In cohort one, characterized by 471 DNA samples extracted from tissue, we analyzed EGFR, 
KRAS, BRAF and HER2 by DS; EGFR by SensiScreen
®
; ALK, ROS1 by FISH and TTF-1 by 
IHC. The second cohort, characterized by 61 tissue, 39 plasma and 5 serum samples was 
characterized by cobas
®
 (Roche) for EGFR alterations, by SensiScreen
®
 liquid biopsy kit for 
T790M mutation in EGFR exon 20 (PentaBaseApS) and by SensiScreen
® 
tissue kit 
(PentaBaseApS) for the other EGFR mutations. In some cases of cohort two, we also had 
EGFR mutation data from previous TheraScreen
® 
and IOT analyses. 
In the first cohort, the characterization of the main lung AC molecular markers and of TTF-1 
was necessary to evaluate if our cohort can be considered representative of a standard 
population. In particular, we detected EGFR, KRAS, BRAF and HER2 mutations in 14.3%, 
23.3%, 1.7% and 0.4% of cases, respectively. In particular, in the group of EGFR mutant 
patients, the different exons (18, 19, 20 and 21) are altered in 5.6%, 39.4%, 21.2% and 33.8% 
of cases, respectively. By FISH, we found ALK and ROS1 rearrangements in 3.6% and 0.4% 
of patients, respectively, and TTF-1 nuclear expression was observed in 78.5% of cases. All 
these rates are superimposable with those reported in the literature for Caucasian population 
(Rosell R et al, 2012). 
Statistical analyses confirmed that EGFR and KRAS are nearly mutually exclusive (only one 
case harbours mutations in both genes). In addition, we observed a significant association of 
KRAS/BRAF wild-type sequences and TTF-1 expression: to the best of our knowledge, it is 
the first time that such correlation has been reported (Gerber DE et al, 2014).  
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In cohort one is also highlighted the presence of T790M, the most important mechanism of 
resistance to EGFR TKIs (Murray S et al, 2012; Santarpia M et al, 2017): in particular, 4 
cases harbor the T790M mutation alone, demonstrating that T790M can be a mechanism of 
primary resistance as well. These data confirm the necessity to analyze EGFR exon 20 also in 
patients that have not already been treated by EGFR TKIs because they could show primary 
resistance. 
Moreover a deeper exam of the results highlights that, in cohort one, the S768I mutation is 
always associated with other EGFR mutations. This association could have a biological 
significance but, until now, literature reported no explanation to this event and the few 
reported data concerning this mutation are contradictory (Yang JC et al, 2015; Banno E et al, 
2016). Some papers report that patients harbouring the S768I demonstrate a good response to 
2
nd
G TKIs like afatinib (Gilotrif
®
 or Giotrif
®
; Boehringer Ingelheim, Germany), whereas 
other articles report that the clinical benefit obtained from EGFR TKIs is higher in NSCLC 
patients with common EGFR mutations than in those with uncommon EGFR mutation types 
(e.g. S768I) (Yang JC et al, 2015; Banno E et al, 2016; Chen K et al, 2017). The difficult 
interpretation of S768I influence on TKIs benefit could be associated with the fact that this 
alteration is mainly detected in concomitance with other mutations which define the response 
to targeted therapies and hide the effect of this alteration. However, we could hypothesize that 
S768I in trans with the other mutation could give lower response to TKIs. The evidence that, 
in our cohort, all the patients with the S768I change carry another EGFR mutation, strongly 
suggests the S768I is insufficient for a full activation of EGFR. 
In addition, a small, but not negligible subgroup of our cohort one (0.85% of cases) carries 
two different oncogene alterations: this finding demonstrates that, in general, oncogene 
mutations are mutual exclusive in lung cancer, but there are real cases showing a double 
activation, where the efficacy of targeted therapies may be altered due to this unusual 
molecular pattern. In fact, EGFR and ALK therapies displays great efficacy when the EGFR 
or ALK activation, respectively, is detected alone; whereas it is still debated what happens 
when more mutations are simultaneously present. To date, only few studies have investigated 
this issue. Literature reports that patients showing concomitant KRAS and EGFR mutations 
experience a poorer clinical outcome after treatment with EGFR TKIs (i.e. erlotinib) when 
compared to cases characterized by EGFR mutations only (Eberhard DA, 2005). In addition, 
another study describes that patients harbouring concomitant EGFR mutation and ALK 
rearrangement might still benefit from ALK inhibitors regarding disease stabilization; 
however, the administration of EGFR TKIs is associated with less efficacy in comparison to 
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samples mutated only in EGFR gene (Sahnane N et al, 2015). The same study shows that the 
efficacy of TKIs against ALK is unclear in patients carrying a simultaneous KRAS mutation 
and ALK rearrangement: the authors show patients who benefit from crizotinib, but also 
patients who are primarily resistant to such therapy. All these data highlight that double 
alterations in EGFR, KRAS and ALK genes are not only induced by drug administration, but 
they may occur in the primary tumor, probably due to tumor heterogeneity, thus reinforcing 
the importance of the determination of a wide range of genes with NGS and FISH to better 
define the real efficacy of targeted therapies. Indeed, in the future, other known and unknown 
genes alterations (e.g. BRAF mutations) could determine and influence, beside KRAS,  the 
response to these drugs.  
Afterwards we used the first cohort for the comparison of DS with the new, more sensitive 
real-time PCR-based assay, SensiScreen
®
, in order to improve the molecular diagnosis of 
EGFR mutations. To characterize the new assays, at first we performed sensitivity studies on 
plasmids comprising sequences with different EGFR mutations and then on DNA extracted 
from EGFR mutant cell lines. By applying changes in the concentration and in the chemical 
structures of SensiScreen
®
 reagents, we succeeded in the development of a new EGFR real-
time PCR assay characterized by a LOD between 0.1% and 1% (corresponding to the 
detection of until 1 copy of mutant DNA in a wt background). This value means that we will 
be able to identify the presence of a specific mutation also in tumor samples where 
mutant clones are highly dispersed (for tumor heterogeneity or for normal cells 
infiltration). After validation, we tested the new EGFR assay on cohort one. The samples 
were tested by G719A, G719C, G719S, S768I, T790M, L858R, L861Q simplex kits and by 
G719 mutations, exon 19 deletions, exon 20 insertions multiplex kits. The new assays 
confirmed the EGFR mutations previously detected by DS and, more importantly, identified 
14 additional mutations: in details, 4 new exon 19 deletions, 2 exon 20 insertions, 2 T790M 
mutations in exon 20, 5 L858R mutations and 1 L861Q mutation in exon 21. The overall 
percentage of EGFR mutations detected by the new assays corresponds to a global increase of 
26% of mutated cases. The new methodology did not find additional G719 (exon 18) and 
S768I (exon 20) mutant cases. Three samples, resulting not evaluable by DS, were defined as 
wt by SensiScreen
®
 demonstrating that this new real-time PCR assay is able to identify 
mutations also in samples containing DNA fragments of little dimensions. This feature is 
related to the minor size of amplicons obtained by the application of this new assay. 
The additional mutations discovered by the new real-time PCR assays can be explained by the 
different LOD of the two methodologies (10-20% for DS vs 0.1-1% for SensiScreen
®
) and 
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this evidence suggests the adoption of these new assays in the laboratories of molecular 
pathology. Indeed, 12 patients of our cohort were addressed to standard chemotherapies 
instead of EGFR-targeted therapies, which are more efficient in EGFR-mutant cases.  
We can notice that two new mutant samples (number 156 and 256; Table 4.5) are 
characterized by another EGFR mutation; this indicates that the discrepancy between DS and 
PentaBase assays sometimes could be due to the tumor heterogeneity since the new 
methodology, based on a better sensitivity, is able to detect both mutations in the tumor 
specimen even if one of the alterations is representative of only a little percentage of cancer 
cells. These two cases resulted, respectively, 746_750del and L858R mutant by DS but the 
new methodology found also T790M mutation. As a consequence of DS results these patients 
were treated by 1
st
G TKIs even if T790M confers resistance. Unfortunately, clinical data for 
these patients are not available. 
In last years, SensiScreen
® 
has been developed and validated also for BRAF, KRAS and NRAS 
genes in cohorts of colorectal cancer (CRC) and melanoma patients (Riva A et al, 2017). Also 
with these kits we found, by comparing the results to Sanger sequencing data, new CRC and 
melanoma mutated samples demonstrating that the higher sensitivity is an advantage of all 
SensiScreen
® 
assays. Other peculiarities of these new methodologies are the speed and 
simplicity of execution and the uniformity in the interpretation of results between the different 
assays of the aforementioned genes. 
To sum up, all the advantages of SensiScreen
®
 lung can give benefit to the care of lung AC 
patients. First of all, the detection of new mutated samples enlarges the cohort of patients that 
could benefit from the EGFR predictive role of response to EGFR TKIs. Indeed the patients 
wt by DS, but mutated by PentaBase kit, would be not treated with targeted therapies against 
EGFR or, in contrast, they would be treated with TKIs even if they harbor a mutation of 
resistance (e.g. T790M). Secondly, patients resulting not evaluable by DS but evaluable by 
SensiScreen
®
 can avoid a re-biopsy for a new determination of EGFR molecular status. 
Beside SensiScreen
® 
and DS, a huge number of methodologies are available on the market to 
characterize EGFR mutations in DNA extracted from tissue biopsies. Many studies report a 
comparison between different approaches and these data could be compared to the new 
PentaBase kit. An example is the use of cobas
®
 kit for tissue (Roche). A study describes that 
cobas
®
 (Roche) showed high concordance rates between three laboratory-developed tests (i.e. 
PCR clamp, PCR invader, Cycleave assays) and permits to find new mutated cases 
(Nakamura H et al, 2017). However, cobas
® 
(Roche) is less sensitive than PentaBase assays 
even if they are based on the same methodology (i.e. real-time PCR). This fact is particularly 
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clear if we observe the different LOD for the detection of T790M mutation in tissue samples 
(2-3% for cobas
®
 vs 0.1-1% for SensiScreen
®
). Another assay that could be used for EGFR 
characterization is ddPCR. This methodology has a sensitivity equal to 0.1% comparable to 
the one of SensiScreen
®
. Literature reports that ddPCR has a superior analytical performance 
and equivalent or higher clinical performance than cobas
®
 (Roche) (Kim SS et al, 2018). 
Consequently, also the new PentaBase assays should be better than cobas
® 
(Roche) for EGFR 
characterization in tumor tissues. Moreover, SensiScreen
®
 can be defined as the better 
approach because it is easier, faster, and cheaper than ddPCR, a technique that requires highly 
trained personnel. 
All these high-sensitive techniques, including PentaBase, permit to detect very small 
percentages of EGFR mutant cells in the specimens. The presence of a small amount of DNA 
mutant copies in the sample could be due to either tumor heterogeneity, or to the fact that the 
majority of lung AC samples are small biopsies or to the possible oversights happening during 
the tumor area selection. The real clinical value of little clones is still debated. However, some 
studies report the importance of the determination of allelic alterations, also in a small amount 
of clones, for an accurate definition of the response to targeted therapies. Indeed, literature 
reports that the application of highly sensitive methods for KRAS mutation detection (e.g. 
mutant enriched PCR or engineered mutant enriched PCR) may improve the identification of 
anti-EGFR antibodies resistance, at least in CRC patients (Molinari F et al, 2011). 
 
The previous characterization of EGFR by SensiScreen
® 
was done on DNA extracted from 
FFPE tissues but recent studies described the importance of the definition of the molecular 
markers gene status also in ctDNA from liquid biopsies, especially in plasma. The 
characterization of molecular markers on liquid biopsies has a wide range of advantages 
compared to tissue biopsies: they are not invasive (so analyses can be repeated serially in 
short times), they better reflect tumor heterogeneity and constant evolution of tumors; they are 
always possible, they are more cost-effective and ctDNA represents multiple metastatic sites 
simultaneously (Burrell RA and Swanton C, 2014; Strotman LN et al, 2016). In addition, 
liquid biopsies provide a good substitute to tissue biopsies when the tissue sample cannot be 
collected because of cancer localization or patient’s unhealthy conditions. 
Beside these advantages, liquid biopsies show two main disadvantages. Firstly, they cannot be 
used for the detection of molecular markers alterations in lesions located in brain or bones, 
since the blood-brain barrier and the low vascularisation of bone tissue cause a significant 
decrease or absence of ctDNA in plasma. Secondly, ctDNA is, generally, highly fragmented 
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and low concentrated (Burrell RA and Swanton C, 2014; Strotman LN et al, 2016), thus 
requiring methodologies characterized by high sensitivity. 
The little number of disadvantages is completely negligible compared to the huge number of 
advantages, indeed the prospective of a better care for patients affected by cancer brought to 
the development of analyses on liquid biopsies. Consequently, we decided to develop and 
validate on plasmids and on EGFR mutant cell lines, in collaboration with PentaBase ApS, a 
real-time PCR assay for T790M analyses on liquid biopsies (SensiScreen® T790M liquid 
biopsy assay). 
On the basis of the high aggressiveness of lung AC, we choose to start the development of the 
assay on the most important mutation of resistance of this histotype in order to be able to 
monitor the development of resistance to EGFR targeted therapies in short times.   
First of all, sensitive assays on plasmids and cell lines reported that also this kit for liquid 
biopsies has LOD of 0.1%, corresponding to the detection of until 1 copy of mutant DNA in a 
wt background. After the validation we applied this assay, on plasma and serum samples of a 
second cohort. In addition, we evaluated plasma, serum and tissue samples of cohort two by 
the simplex and multiplex tissue kit specific for the different EGFR alterations described 
previously. In order to confirm SensiScreen
® 
results, we applied also cobas
®
 (Roche) 
methodology in some samples for which we had enough material and we compared the data. 
Interestingly, some patients were previously characterized by DS, IOT Oncomine cell-free 
nucleic acids assay (Thermo Fisher Scientific) or TheraScreen® (QIAGEN). In plasma, serum 
and tissue samples, SensiScreen
® 
confirmed all the data obtained by the other methodologies 
and, compared to TheraScreen
® 
(QIAGEN), it was able to evaluate four samples that were 
defined as not evaluable. In addition in two plasma samples it succeeded in the detection of 
new L858R mutations compared to TheraScreen
®
 and cobas
®
 (Roche) (corresponding to 14% 
of cases). These two patients, classified as L858R negative by cobas
®
 (Roche) and 
TheraScreen
® 
(QIAGEN) techniques on DNA from plasma, were subjected to a subsequent 
tissue biopsy for the molecular characterization, although the clinical conditions of the 
patients were not completely good. In tissue, cobas
®
 (Roche), TheraScreen
® 
(QIAGEN) and 
SensiScreen
®
 assays demonstrated the presence of the L858R change. So, we can conclude 
that the application of SensiScreen
®
 may prevent the use of tissue biopsies, which could be 
the source of side effects for the patients. Moreover, liquid biopsies testing influences the 
costs because they are cheaper and can avoid the repetition of tissue biopsies. The 
aforementioned data demonstrate that SensiScreen
® 
is a good technique also for testing in 
liquid biopsies and can find a higher number of mutated cases than other methodologies. The 
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discovery of new mutated samples and the ability to characterize also the specimens that were 
not evaluable by other techniques can improve, influence and change the decision concerning 
the administration of targeted treatments and it is due to the higher sensitivity of 
SensiScreen
®
. Indeed the minor size of amplicons obtained by PentaBase assays define an 
LOD equal to 0.1-1%; whereas the sensitivities of DS, TheraScreen
® 
(QIAGEN) and cobas
® 
(Roche) are 9%, 1% and 2-5% respectively (Sholl LM et al, 2016; Sorber L et al, 2016). It is 
important to underline that, in all the methodologies, sensitivity differs on the basis of the 
mutation that is analysed and generally T790M mutation assays present the lowest sensitivity 
(Thress KS et al, 2016). 
SensiScreen
® 
should be preferable than Oncomine cell-free nucleic acids assay (Thermo 
Fisher Scientific), even if the LOD of IOT (Thermo Fisher Scientific), equal to up to 0.1%, is 
similar to the sensitivity of PentaBase assays (Sholl LM et al, 2016; Sorber L et al, 2016). 
Indeed, even if NGS approach gives information about multiple genes in one run, we have to 
consider that SensiScreen
® 
data analyses and experiments are easier, faster (it takes only 90 
minutes) and are less expensive in both tissue and liquid samples. The decision of the better 
approach to test liquid biopsies is complicated but we could define that NGS appears to be the 
most appropriate technique for use at the time of diagnosis. Subsequently, in the follow up 
period, we could concentrate our attention in only one gene and we could use a candidate-
gene approach involving mutation-specific techniques (e.g. SensiScreen
®
, TheraScreen
®
 or 
cobas
®
) in order to benefit from their advantages (i.e. low costs, simpler and faster workflow, 
easier data management). The determination of the methodology to apply is based on the 
sensitivity but depends also on the kind of mutation that we want to study. For example, the 
detection of C797S mutation is not possible with cobas
® 
assay but is possible by IOT, but at 
the moment its clinical relevance is marginal because there are no drugs targeting such 
alteration. 
Beside the aforementioned assays, applied in the second cohort of my project, many other 
tests can be considered for EGFR characterization in liquid biopsies. Some innovative assays 
are ddPCR, and BEAMing qPCR. These methodologies are defined by a LOD that is 
comparable to SensiScreen but they need trained personnel and they are more difficult, more 
expensive than PentaBase assays. Many papers report comparisons between NGS, ddPCR, 
BEAMing qPCR demonstrating that these assays characterize the same quantity of mutations. 
In literature these assays identify higher rates of mutated cases compared to cobas
® 
(Roche) 
(Thress KS et al, 2015; Sholl LM et al, 2016; Sorber L et al, 2016; Feng Q et al, 2018). As a 
consequence we can hypothesize that a comparison between SensiScreen and ddPCR or 
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BEAMing qPCR could give a higher correspondence, for what concerns the mutated cases, 
than cobas (Roche) because these methodologies, like IOT (ThermoFisher), have a high LOD 
that is similar to the new PentaBase assays. Consequently, PentaBase results could find a 
higher correspondence with the data obtained by methods characterized by high sensitivity 
and specificity (e.g. IOT, ddPCR, BEAMing qPCR) than with cobas® (Roche) or 
TheraScreen
® 
(QIAGEN). 
 
The second aim of my research project was the investigation of a new molecular marker for 
targeted therapies. In particular, we decided to study ROR1, a transmembrane protein 
belonging to the receptor TK family whose endogenous ligand has not been discovered yet. 
Its expression is peculiar because it is found during embryo-development but it is not present 
in normal adult tissues (Rebagay G et al, 2012). However, recent studies report ROR1 
expression in tumor tissues (e.g. B-CLL, B-ALL, MCL) and in breast cancer cell lines 
(Baskar S et al, 2008; DaneshManesh AH et al, 2008; Shabani M et al, 2008; Zhang S et al, 
2012). ROR1 oncogenic activity is related to PI3K-AkT-mTOR pathway activation that 
brings to the enhancement of cellular migration, proliferation and survival (Rebagay G et al, 
2012). Interestingly, one paper reports, in NSCLC, a significant association between ROR1 
and TTF-1, the most important AC marker (Yamaguchi T et al, 2012). The ROR1 expression 
profile detected in cancers and its demonstrated association with TTF-1 led us to the 
investigation of its role as a new putative marker of response to targeted therapies in lung AC. 
This hypothesis arise from the fact that targeted therapies developed against ROR1 should be 
effective and specific only against tumour cells and consequently should not act against 
normal cells, because this receptor is found only in tumor cell lines and tissues (Baskar S et 
al, 2008; DaneshManesh AH et al, 2008; Shabani M et al, 2008; Rebagay G et al, 2012; 
Zhang S et al, 2012).  
To determine whether ROR1 could be a promising new marker in lung AC, we evaluated its 
expression in the third cohort of this project. For this purpose, we selected a different cohort, 
characterized by 102 lung AC cases, because we need to test a group of patients with clear 
OS, PFS and treatment data. The patients were characterized for EGFR, KRAS, BRAF, HER2, 
ALK and ROS1 molecular alterations by DS or FISH. These assays confirmed that, as 
previously described for cohort one, the third cohort is a representative population with rates 
of mutations similar to those described in the literature (Takeuchi T et al, 2006; Rikova K et 
al, 2007; Herbst RS et al, 2008; Michaloglou C et al, 2008; Gerber DE et al, 2014). In the 
third cohort TTF-1 expression was evaluated by IHC and 74.3% out of the evaluable cases 
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showed nuclear expression of this protein demonstrating the importance of this transcriptional 
factor as a fundamental marker for lung AC histotype (Rosell R et al, 2012).   
The molecular and clinical-pathological data correlations were investigated through the 
application of the two-tailed Fisher’s exact statistical test. Statistics failed to demonstrate 
significant correlations between the clinical-pathological characteristics and the molecular 
data, if we exclude the mutual exclusivity of EGFR and KRAS mutations.  
Then, ROR1 expression was tested by TaqMan real-time PCR and the results were compared 
in normal and tumour tissues of the same patient by the application of the Livak method. The 
analyses were done only on the samples for which we had sufficient tissue material left for 
RNA extraction. ROR1 overexpression was detected in 28.6% out of the evaluable cases. The 
data obtained by ROR1 real-time demonstrated that this gene could be a new molecular 
marker for specific targeted therapies (now under evaluation in B-ALL, B-CLL, MCL and 
breast cancer cell lines and on animal models), because its mRNA is found in a not negligible 
number of lung AC samples, compared to or even higher than EGFR (Baskar S et al, 2008; 
DaneshManesh AH et al, 2008; Shabani M et al, 2008). 
Even if our results are promising, we found an expression rate that is lower compared to the 
values reported in the literature: indeed, a single study, published in 2012, demonstrated that 
ROR1 (as evaluated by IHC) is expressed in 77% of lung cancers (Zhang S et al, 2012). This 
discrepancy can be explained by the different methodologies that we applied, or by the 
different ethnicity of the group analysed in literature. In fact, Zhang and colleagues evaluated 
ROR1 by IHC but we decided to estimate ROR1 expression by real-time PCR because the 
interpretation is more objective and because, to date, no commercial, standardized ROR1 
antibodies have been developed (Zhang and colleagues used an home-made antibody). 
Furthermore, IHC and real-time PCR analyse ROR1 expression in two different molecular 
levels, protein and mRNA (respectively); as a consequence, expression data could be 
discordant between these two assays due to different mechanisms of regulation. Another fact 
that could explain the different rates of ROR1 expression between our data and those included 
in the paper of Zhang and colleagues is that this study investigated an Asian cohort whereas 
our experiments were conducted on a Caucasian cohort. Indeed, diversities between Asian 
and Caucasian populations exist in the mutational landscapes of lung AC: for example, in 
Asian patients the percentage of lung cancer ACs characterized by EGFR mutations is 
significantly higher compared to Caucasian patients (i.e. 70% in Asian patients compared to 
20% in Caucasian population) and a similar discrepancy cannot be excluded also for ROR1 
expression (Vargas AJ et al, 2016). 
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On the other hand, ROR1 expression is not correlated with any other molecular or clinical-
pathological data, if we exclude a tendency of ROR1 overexpression in advanced stage cases, 
and no significant correlation was demonstrated between ROR1 and PFS, OS or treatment. 
Noticeably, we found no correlation even between ROR1 and TTF-1. This could be due to the 
little number of patients for which we have assessed ROR1 and TTF-1 at first, or to the 
presence in the literature of only one study concerning the association between these two 
markers. In addition, also the ethnic differences could justify the discrepancy, indeed the 
values reported on the paper written by Yamaguchi T and colleagues were obtained in an 
Asian cohorts whereas we investigated Caucasian patients (Yamaguchi T et al, 2012).  
To conclude, in the third cohort we decided to examine in depth the mechanism of ROR1 
regulation in lung AC, starting from a recent study where the role of miRNA was evaluated 
with respect to ROR1 expression (Tan H et al, 2016). This study reports that a particular 
miRNA, miR-382, inhibits ROR1 through its hybridization with the mRNA of this tyrosine 
kinase receptor. In particular, the Authors highlighted that miR-382 binds ROR1 mRNA in 
the ROR1 3`-UTR region. In addition, they found that, in cell line models, the overexpression 
of miR-382 suppresses proliferation, migration and invasion in ovarian cancer cells (Tan H et 
al, 2016). These results are correlated to the role of tumor suppressor gene exploited by miR-
382 through the inhibition of ROR1. 
On these bases, we evaluated miR382 expression in our third cohort, and we found that in 
48.1% out of the evaluable cases the miR-382 resulted over-represented in tumour cells if 
compared to normal tissue cells. This finding may justifies the low number of cases 
overexpressing ROR1 in our cohort, although statistical analyses (Sperman and Pearson 
correlation coefficient, two-tailed Fisher’s exact test) did not show any significant correlation 
between ROR1 and miR-382 expression. This datum, however, deserves confirmation in a 
larger cohort, since we evaluated only 58 cases. 
The relevance of miR-382 is related to its role in ROR1 regulation but may also play a role in 
the clinical setting, since miR-382 overexpressing patients should be less responsive to ROR1 
therapies because this miRNA inhibits the oncogenic role of this tyrosine kinase receptor. In 
addition, miR-382 and ROR1 could be also prognostic markers because it has been 
highlighted that patients affected by cancer with high expression levels of ROR1 (i.e.: ovarian 
tumor) have a higher rate of relapse and a shorter median survival than patients expressing 
low levels of ROR1 (Zhang S et al, 2014). 
In conclusion in my PhD project we developed a new more sensitive methodology for EGFR 
characterization in tissue and plasma samples and we studied ROR1 as a putative marker of 
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new molecular targeted therapies, which can enlarge the number of patients potentially 
treatable with targeted therapies. Our data suggest that the assays developed in collaboration 
with a Danish company may be introduced in clinical practice, with evident benefit for 
patients and for laboratories. As for ROR1, the characterization of this marker needs to be 
confirmed in larger cohorts, but our data are promising, especially if ROR-1 targeted therapies 
will be introduced into the clinical setting. Indeed a consistent fraction of lung AC (at least 
one fourth of Caucasian people, on the basis of our preliminary data) may be considered for 
the treatment with such therapies.  
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